
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancers (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Cancers (Basel)</journal-id><journal-id journal-id-type="publisher-id">cancers</journal-id><journal-title-group><journal-title>Cancers</journal-title></journal-title-group><issn pub-type="epub">2072-6694</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">31216772</article-id><article-id pub-id-type="pmc">6628160</article-id><article-id pub-id-type="doi">10.3390/cancers11060846</article-id><article-id pub-id-type="publisher-id">cancers-11-00846</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Targeted Therapy of Uveal Melanoma: Recent Failures and New Perspectives</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Croce</surname><given-names>Michela</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ferrini</surname><given-names>Silvano</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0872-4671</contrib-id><name><surname>Pfeffer</surname><given-names>Ulrich</given-names></name></contrib><contrib contrib-type="author"><name><surname>Gangemi</surname><given-names>Rosaria</given-names></name><xref rid="c1-cancers-11-00846" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-cancers-11-00846">IRCCS Ospedale Policlinico San Martino, 16132 Genoa, Italy; <email>michela.croce@hsanmartino.it</email> (M.C.); <email>silvanodomenico.ferrini@hsanmartino.it</email> (S.F.); <email>patologia.molecolare.integrata@gmail.com</email> (U.P.)</aff><author-notes><corresp id="c1-cancers-11-00846"><label>*</label>Correspondence: <email>rosaria.gangemi@hsanmartino.it</email></corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2019</year></pub-date><volume>11</volume><issue>6</issue><elocation-id>846</elocation-id><history><date date-type="received"><day>13</day><month>5</month><year>2019</year></date><date date-type="accepted"><day>11</day><month>6</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Among Uveal Melanoma (UM) driver mutations, those involving <italic>GNAQ</italic> or <italic>GNA11</italic> genes are the most frequent, while a minor fraction of tumors bears mutations in the <italic>PLCB4</italic> or <italic>CYSLTR2</italic> genes. Direct inhibition of constitutively active oncoproteins deriving from these mutations is still in its infancy in UM, whereas <italic>BRAFV600E</italic>-targeted therapy has obtained relevant results in cutaneous melanoma. However, UM driver mutations converge on common downstream signaling pathways such as PKC/MAPK, PI3K/AKT, and YAP/TAZ, which are presently considered as actionable targets. In addition, <italic>BAP1</italic> loss, which characterizes UM metastatic progression, affects chromatin structure via histone H2A deubiquitylation that may be counteracted by histone deacetylase inhibitors. Encouraging results of preclinical studies targeting signaling molecules such as MAPK and PKC were unfortunately not confirmed in early clinical studies. Indeed, a general survey of all clinical trials applying new targeted and immune therapy to UM displayed disappointing results. This paper summarizes the most recent studies of UM-targeted therapies, analyzing the possible origins of failures. We also focus on hyperexpressed molecules involved in UM aggressiveness as potential new targets for therapy.</p></abstract><kwd-group><kwd>uveal melanoma</kwd><kwd>driver mutations</kwd><kwd>signaling pathways</kwd><kwd>targeted therapies</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-cancers-11-00846"><title>1. Introduction</title><p>Although overall survival (OS) of Uveal Melanoma (UM) patients is relatively high, reaching about 80% at 5 years, with high-risk UM patients frequently developing a metastatic disease, which has a severe prognosis. In about 90% of cases, metastases involve the liver, and untreated patients have a mean survival time of about 2 months, reaching about 6 months in treated patients [<xref rid="B1-cancers-11-00846" ref-type="bibr">1</xref>,<xref rid="B2-cancers-11-00846" ref-type="bibr">2</xref>,<xref rid="B3-cancers-11-00846" ref-type="bibr">3</xref>]. While in metastatic cutaneous melanoma targeted therapies with B-Raf Proto-Oncogene, Serine/Threonine Kinase (B-RAF) and Mitogen-Activated Protein Kinase Kinase (MEK) inhibitors or immunotherapy with anti-Cytotoxic T-Lymphocyte Associated Protein (CTLA)-4 and/or anti- Programmed Cell Death (PD)-1/ Programmed Cell Death 1 Ligand (PDL)-1, treatments are highly effective [<xref rid="B4-cancers-11-00846" ref-type="bibr">4</xref>], no effective standard treatment is available for metastatic UM so far. Indeed, a recent meta-analysis of OS after different treatments for metastatic UM showed no significant difference by treatment modality [<xref rid="B5-cancers-11-00846" ref-type="bibr">5</xref>].</p><p>Recent advances in the understanding of the genetic differences between cutaneous and uveal melanoma point out the need of specific treatments for UM. In particular, mutually exclusive activating mutations involve the <italic>GNAQ</italic> or <italic>GNA11</italic> genes [<xref rid="B6-cancers-11-00846" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-00846" ref-type="bibr">7</xref>], which encode for G&#x003b1; subunits of G-proteins and drive oncogenesis in most of UM. Additional driver mutations involve the <italic>PLCB4</italic> [<xref rid="B8-cancers-11-00846" ref-type="bibr">8</xref>] or the Cysteinyl Leukotriene Receptor 2 (<italic>CYSLTR2)</italic> genes [<xref rid="B9-cancers-11-00846" ref-type="bibr">9</xref>], in a minor fraction of UM cases.</p><p>In addition to driver mutations, monosomy of chromosome 3 [<xref rid="B10-cancers-11-00846" ref-type="bibr">10</xref>,<xref rid="B11-cancers-11-00846" ref-type="bibr">11</xref>,<xref rid="B12-cancers-11-00846" ref-type="bibr">12</xref>], loss of chromosome 3 heterozygosity [<xref rid="B13-cancers-11-00846" ref-type="bibr">13</xref>], and inactivating mutations of the BRCA1-associated protein 1 (<italic>BAP1</italic>) oncosuppressor gene [<xref rid="B14-cancers-11-00846" ref-type="bibr">14</xref>] are highly associated with the metastatic risk. Differently, somatic mutations in <italic>EIF1AX</italic> and <italic>SF3B1</italic> genes specifically occur in UMs with disomy 3, which rarely undergo metastatic progression [<xref rid="B15-cancers-11-00846" ref-type="bibr">15</xref>]. Importantly, <italic>BAP1</italic> loss-of-function mutations correlate with a distinct DNA methylation profile [<xref rid="B16-cancers-11-00846" ref-type="bibr">16</xref>]. </p><p>An important difference between uveal and cutaneous melanoma is related to the mutational load, which is typically high in cutaneous melanoma, in relation to UV exposure [<xref rid="B17-cancers-11-00846" ref-type="bibr">17</xref>], and low in UM [<xref rid="B16-cancers-11-00846" ref-type="bibr">16</xref>]. A high mutational load may result in the frequent generation of neo-antigens, which render the cutaneous melanoma highly immunogenic and sensitive to immune-checkpoint blockers such as anti-CTLA-4 [<xref rid="B18-cancers-11-00846" ref-type="bibr">18</xref>,<xref rid="B19-cancers-11-00846" ref-type="bibr">19</xref>] and anti-PD-1 monoclonal antibodies [<xref rid="B20-cancers-11-00846" ref-type="bibr">20</xref>,<xref rid="B21-cancers-11-00846" ref-type="bibr">21</xref>]. On the other hand, these immunotherapies have shown a low impact in metastatic UM outcome so far [<xref rid="B22-cancers-11-00846" ref-type="bibr">22</xref>,<xref rid="B23-cancers-11-00846" ref-type="bibr">23</xref>].</p><p>This review summarizes the status of targeted therapies, which are undergoing clinical testing in metastatic UM, and discusses new therapeutic possibilities emerging from recent advances in UM genetics and biology [<xref rid="B3-cancers-11-00846" ref-type="bibr">3</xref>,<xref rid="B24-cancers-11-00846" ref-type="bibr">24</xref>]. In particular, we discuss the possibilities to target oncogenic G&#x003b1; proteins, G&#x003b1; down-stream pathways, UM cell chromatin structure and transcriptional programs or overexpressed molecules involved in UM metastatic progression (<xref ref-type="fig" rid="cancers-11-00846-f001">Figure 1</xref>).</p></sec><sec id="sec2-cancers-11-00846"><title>2. Targeting Driver Mutations</title><p>Targeting of driver mutations such as the <italic>B-RAF V600E</italic> by small-molecule inhibitors has provided a therapeutic option for a subset of cutaneous melanomas bearing such a mutation, although responses are transient. However, <italic>B-RAF</italic> mutations only rarely occur in UMs, which in about 90% of cases bear an activating mutation of the <italic>GNAQ/GNA11</italic> genes, driving tumor initiation [<xref rid="B6-cancers-11-00846" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-00846" ref-type="bibr">7</xref>]. In the G&#x003b1;Q or G&#x003b1;11 Q209L mutant proteins, the catalytic glutamine is substituted by leucine, leading to the loss of Guanosine Triphosphate hydrolase (GTPase) activity. Therefore, these mutated proteins retain prolonged binding with GTP, leading to constitutive activation. The R183C mutation is less frequent and has been predicted to display a less strong inhibitory activity on G&#x003b1;Q or G&#x003b1;11 [<xref rid="B7-cancers-11-00846" ref-type="bibr">7</xref>]. <italic>GNAQ/11</italic> Q209L mutations are early or initiating events, which are present at any stage of UM [<xref rid="B25-cancers-11-00846" ref-type="bibr">25</xref>,<xref rid="B26-cancers-11-00846" ref-type="bibr">26</xref>]. However, <italic>GNA11</italic> mutations are more frequently found in UM metastases (57%) than <italic>GNAQ</italic> mutations (22%), suggesting that <italic>GNA11</italic> mutation is associated with higher metastatic risk [<xref rid="B7-cancers-11-00846" ref-type="bibr">7</xref>]. In addition, Q209L mutations in <italic>GNAQ</italic> or <italic>GNA11</italic> have been found in 55% or 7% of blue nevi, respectively [<xref rid="B6-cancers-11-00846" ref-type="bibr">6</xref>,<xref rid="B7-cancers-11-00846" ref-type="bibr">7</xref>]. Mutated G&#x003b1; proteins mediate the activation of the PLC&#x003b1;/PKC pathway and multiple downstream signaling pathways, including the RAF/MEK/ERK, PI3K/AKT/MTOR, and Trio/Rho/Rac/YAP1 pathways [<xref rid="B3-cancers-11-00846" ref-type="bibr">3</xref>,<xref rid="B27-cancers-11-00846" ref-type="bibr">27</xref>]. Therefore, mutated G&#x003b1; proteins or downstream signaling molecules represent potential targets for therapy (<xref ref-type="fig" rid="cancers-11-00846-f001">Figure 1</xref>).</p><p>Less frequently, driver mutations involve the genes encoding for phospholipase C4 (<italic>PLCB4</italic>) [<xref rid="B8-cancers-11-00846" ref-type="bibr">8</xref>] or the G protein-coupled receptor (GPCR) cysteinyl leukotriene receptor-2 (<italic>CYSLTR2</italic>) [<xref rid="B9-cancers-11-00846" ref-type="bibr">9</xref>]. The identification of these alternative driver mutations provides further evidence for the pivotal role of the GPCR pathway in UM pathogenesis and could lead to new therapeutic possibilities in a fraction of UM [<xref rid="B28-cancers-11-00846" ref-type="bibr">28</xref>]. The <italic>PLCB4 D630Y</italic> gain-of-function mutation is mutually exclusive with <italic>GNA11</italic> and <italic>GNAQ</italic> mutations, indicating PLCB4 as a downstream target of G&#x003b1; proteins [<xref rid="B8-cancers-11-00846" ref-type="bibr">8</xref>].</p><p>In view of their frequency as drivers in UM, <italic>GNAQ/11</italic> mutations may represent optimal targets for UM molecular therapies. However, the development of targeted therapy for mutated G&#x003b1; proteins is still in an initial phase. The downregulation of <italic>GNAQ</italic> mutant expression using specific short interfering RNA (siRNA) decreased G&#x003b1;Q protein levels in UM cell lines, resulting in a decrease in Extracellular signal&#x02013;Regulated Kinases (ERK) and AKT Serine/Threonine Kinase (AKT) signaling and in 5&#x02019; Adenosine Monophosphate-activated Protein Kinase (AMPK)-dependent autophagic cell death [<xref rid="B29-cancers-11-00846" ref-type="bibr">29</xref>]. Other studies showed that the delivery of siRNA targeting mutated <italic>GNAQ</italic> through oncolytic viruses [<xref rid="B30-cancers-11-00846" ref-type="bibr">30</xref>] or functionalized gold nanoparticles [<xref rid="B31-cancers-11-00846" ref-type="bibr">31</xref>] inhibits UM cell viability and growth and may be useful for future gene regulatory therapeutic approaches.</p><p>The study of the G&#x003b1;Q-Q209L mutant showed a profound structural similarity between mutated and wild-type proteins, suggesting a limited possibility to generate specific inhibitors for the mutated form. The G&#x003b1;Q bearing the Q209P mutation is also GTPase-deficient and constitutively active but has distinct molecular characteristics. In particular, the different conformation in the switch II region of G&#x003b1;-Q209P modifies the interaction with G&#x003b2;&#x003b3; and regulators of G-protein signaling, suggesting the possibility to develop specific targeting strategies for this mutant [<xref rid="B32-cancers-11-00846" ref-type="bibr">32</xref>]. </p><p>The cyclic depsipeptide FR900359, isolated from the <italic>Ardisia crenata Sims</italic> plant, specifically inhibits the activity of the wild-type G&#x003b1;Q, resulting in vasorelaxant effects on rat aortic arteries [<xref rid="B33-cancers-11-00846" ref-type="bibr">33</xref>]. FR900359 inhibits G&#x003b1;Q/11/14 but not other mammalian G&#x003b1; isoforms, by binding with high affinity to these molecules and acting as a pseudo-irreversible inhibitor. Importantly, it also inhibits ERK1/2 activation, cell proliferation, and migration and induces a more differentiated phenotype in melanoma cell lines with elevated G&#x003b1; activity due to hyperexpression of a wild-type G&#x003b1; or to G&#x003b1;11-R183C or G&#x003b1;Q-Q209L mutations [<xref rid="B34-cancers-11-00846" ref-type="bibr">34</xref>]. A more recent study found that FR900359 also suppressed signaling of mutated G&#x003b1;Q in UM cells, through the allosteric inhibition of the Guanosine Diphosphate/Guanosine triphosphate (GDP/GTP) exchange. In G&#x003b1;Q-mutated UM cells, FR900359 inhibited downstream signaling and cell proliferation and induced melanocytic differentiation. The differentiating activity involved the reactivation of polycomb repressive complex 2, which mediates gene silencing [<xref rid="B35-cancers-11-00846" ref-type="bibr">35</xref>]. Similarly, another report showed that FR900359 inhibits oncogenic signaling in UM cells bearing activating mutations in either G&#x003b1;Q or G&#x003b1;11 and induces cell cycle arrest and apoptosis. In addition, FR900359 prevented colony formation in a 3D-cell culture model of UM cells [<xref rid="B36-cancers-11-00846" ref-type="bibr">36</xref>]. </p><p>A very recent study reported that FR900359 predominantly blocks the ERK signaling pathway rather than the PLC&#x003b2; pathway [<xref rid="B37-cancers-11-00846" ref-type="bibr">37</xref>]. Importantly, FR900359 inhibited the growth of UM xenografts bearing the G&#x003b1;Q-activating mutation, leaving unaffected the growth of xenografts driven by mutated B-RafV600E. Altogether, these studies indicate that FR900359 or its derivatives may represent a new, potential treatment option for UM bearing activating <italic>GNAQ</italic> or <italic>GNA11</italic> gene mutations. The depsipeptide YM-254890 is structurally similar to FR900359 and is a selective inhibitor of the G&#x003b1;Q/11 G proteins. A recent study of the structure&#x02013;activity relationship allowed the development of a simplified analogue YM-19, which proved the most effective G&#x003b1;Q/11 inhibitor among new analogues, opening new possibilities for the design of potent small-molecules suitable for pharmaceutical use [<xref rid="B38-cancers-11-00846" ref-type="bibr">38</xref>].</p></sec><sec id="sec3-cancers-11-00846"><title>3. Inhibition of Signaling Pathways Downstream Activated G&#x003b1;Q/11</title><p>Several signaling pathways are activated downstream of mutation-activated G&#x003b1;Q and G&#x003b1;11, including the Mitogen-Activated Protein Kinase (MAPK), RAF/MEK/ERK, Phosphatidylinositol 3-Kinase/AKT/Mechanistic Target Of Rapamycin Kinase (PI3K/AKT/MTOR), and Trio Rho Guanine Nucleotide Exchange Factor/Ras Homolog Family Member/Rac Family Small GTPase 1/ Yes Associated Protein (Trio/Rho/RAC/YAP1) pathways, and provide several potential targets for therapy (<xref ref-type="fig" rid="cancers-11-00846-f001">Figure 1</xref>, <xref rid="cancers-11-00846-t001" ref-type="table">Table 1</xref>).</p><p>The small GTPase and ADP-ribosylation factor 6, ARF6, is required for oncogenic G&#x003b1;Q signaling through all of these downstream pathways and also for &#x003b2;-catenin signaling. ARF6 mediates the trafficking of G&#x003b1;Q from the cell membrane to intracellular vesicles and of &#x003b2;-catenin to the nucleus. The ARF6-specific small molecule inhibitor NAV-2729 reduced UM cell proliferation in vitro and tumor growth in an orthotopic xenograft model. Therefore, ARF6 should be considered as a potentially actionable target for UM therapy [<xref rid="B44-cancers-11-00846" ref-type="bibr">44</xref>].</p><p>Early preclinical studies demonstrated that MEK inhibitors such as selumetinib (AZD6244, ARRY-142886) [<xref rid="B45-cancers-11-00846" ref-type="bibr">45</xref>] or TAK-733 [<xref rid="B46-cancers-11-00846" ref-type="bibr">46</xref>] inhibit UM cell proliferation and viability in vitro, leading to the development of clinical studies of MEK inhibitors in metastatic UM. An initial clinical study of selumetinib in comparison to chemotherapy (NCT01143402) showed an improvement of response rate (RR) (14 vs. 0%) and of progression-free survival (PFS) (15.9 vs. 7 weeks), but limited effect on OS (11.8 vs. 9.1 months), in the selumetinib arm [<xref rid="B39-cancers-11-00846" ref-type="bibr">39</xref>]. Another phase 1 trial, testing the effects of intermittent selumetinib, is now recruiting metastatic UM patients. The aim of this study is to test higher drug doses to more efficiently block the MAPK pathway and prevent the development of resistance (NCT02768766). A phase 1 dose-escalation study of the MEK inhibitor TAK-733 on 51 patients with advanced solid tumors, including 12 patients with UM, showed limited antitumor activity [<xref rid="B47-cancers-11-00846" ref-type="bibr">47</xref>].</p><p>Further studies tested combinations of MEK inhibitors with other drugs. In the phase 3 study SUMIT (NCT01974752), 129 metastatic UM patients were randomized to receive selumetinib or placebo in combination with the alkylating drug dacarbazine. Selumetinib plus dacarbazine showed no significant improvement in the primary endpoint (PFS) compared with placebo plus dacarbazine [<xref rid="B40-cancers-11-00846" ref-type="bibr">40</xref>]. According to a recent review of 590 case records from six eligible clinical studies, UM is poorly responsive to MEK inhibition independent of the type of inhibitor (selumetinib, trametinib, and binimetinib) and the drug combination used [<xref rid="B48-cancers-11-00846" ref-type="bibr">48</xref>]. </p><p>Preclinical models indicated a cooperative effect of selumetinib and paclitaxel in inducing tumor cell apoptosis [<xref rid="B49-cancers-11-00846" ref-type="bibr">49</xref>]. On this basis, the SelPac clinical phase 2 study will investigate the activity of selumetinib in combination with paclitaxel in UM (EudraCT 2014-004437-22). The potential of new drug combinations to increase the efficacy of selumetinib was recently tested in patient-derived xenograft (PDX) models. Combinations of selumetinib with the ERK inhibitor AZ6197 and the mTORC1/2 inhibitor, vistusertib (AZD2014), were the most effective combination therapies [<xref rid="B50-cancers-11-00846" ref-type="bibr">50</xref>].</p><p>Constitutively active G&#x003b1; proteins trigger the Protein Kinase C (PKC) pathway, through diacylglycerol produced by PLC&#x003b2; activation (<xref ref-type="fig" rid="cancers-11-00846-f001">Figure 1</xref>). Recent findings suggested that the PKC&#x003b4; isoform has a predominant role in UM. Intriguingly, however, the PKC&#x003b4; inhibitor B106 induced apoptosis in several UM cell lines, but apparently independent of activated PKC&#x003b4; [<xref rid="B51-cancers-11-00846" ref-type="bibr">51</xref>]. The pan-PKC inhibitor sotrastaurin (AEB071) decreased the viability of <italic>GNAQ/GNA11-</italic>mutated UM cells in preclinical studies [<xref rid="B52-cancers-11-00846" ref-type="bibr">52</xref>]. A phase 1 study of AEB071 showed one partial response, 47% disease stabilizations, and a PFS of 15.4 weeks, in a cohort of 118 UM patients [<xref rid="B53-cancers-11-00846" ref-type="bibr">53</xref>]. A further phase 1 study of the new-generation PKC inhibitor LXS196 is still recruiting patients (NCT02601378).</p><p>Although the PKC inhibitors AEB071 or AHT956 inhibited MAPK signaling and induced G1 arrest in <italic>GNAQ/11</italic>-mutated UM cells, they failed to induce UM tumor regressions in xenograft models. Instead, combinations of PKC and MEK inhibitors resulted in synergistic effects leading to tumor shrinkage in an UM model in vivo and provided the rationale for the use of these combinations in UM therapy [<xref rid="B54-cancers-11-00846" ref-type="bibr">54</xref>]. However, a phase 1b/2 Study of AEB071 and binimetinib (MEK162) in metastatic UM was terminated before the initiation of the phase 2 part (NCT01801358).</p><p>The PI3K/AKT/MTOR pathway is constitutively activated by oncogenic G&#x003b1; signaling. A preclinical study showed that the combination of the MEK inhibitor GSK1120212 and the pan-PI3K inhibitor GSK2126458 cooperatively induced apoptosis in the majority of UM cell lines, in a <italic>GNAQ/11</italic> mutant-dependent manner, while PI3K inhibition &#x0201c;per se&#x0201d; had limited effect [<xref rid="B55-cancers-11-00846" ref-type="bibr">55</xref>]. Further, the PI3K-&#x003b1; inhibitor BYL719 blocked phosphorylation of AKT but had a limited antiproliferative activity in a panel of UM cell lines. However, its combination with the PKC inhibitor AEB071 showed synergistic effects on proliferation and survival of UM cells and inhibited tumor growth in a <italic>GNAQ</italic>-mutated UM xenograft model [<xref rid="B56-cancers-11-00846" ref-type="bibr">56</xref>]. These findings supported the requirement of a simultaneous inhibition of PI3K and different downstream pathways for combination therapies of UM and promoted the design of a clinical phase 1 study to define the safety, tolerability, and maximum tolerated dose (MTD) of the AEB071 and BYL719 drug combination in metastatic UM (NCT02273219).</p><p>The combination of selumetinib with the AKT inhibitor MK2206 induced activation of AMP-activated protein kinase and resulted in the synergistic induction of autophagic cell death in UM cells in vitro [<xref rid="B29-cancers-11-00846" ref-type="bibr">29</xref>]. In addition, this combination was effective in inhibiting UM growth in xenograft models. These data led to the design of a phase 2 clinical trial of trametinib with or without the AKT inhibitor GSK795, but this combination failed to improve PFS and RR with respect to the single selumetinib arm [41 (NCT01979523).</p><p>Other studies focused on MTOR as potential target for combination therapies. A clinical phase 2 study (NCT01252251) tested whether combined treatment with the MTOR inhibitor everolimus and the somatostatin receptor agonist pasireotide would be efficacious in metastatic UM. This combination had limited clinical benefit in 13 evaluable patients and required dose reductions for side-effects [<xref rid="B42-cancers-11-00846" ref-type="bibr">42</xref>]. A combination screening with several small molecule inhibitors inhibiting PKC, MEK, AKT, PI3K, and MTOR in a panel of UM cell lines showed a potent synergy between the MTOR inhibitor everolimus and the PI3K inhibitor GDC0941. This drug combination showed enhanced pro-apoptotic effects in vitro and in two PDX models. The molecular basis of this synergy was related to the ability of GDC0491 to block the reactivation of AKT induced by everolimus [<xref rid="B57-cancers-11-00846" ref-type="bibr">57</xref>]. Another screening study using a panel of UM PDXs found that the two small molecules CGM097 (p53-MDM2 inhibitor) and RAD001 (mTORC1 inhibitor) has synergistic effects with the PKC inhibitor AEB071, demonstrating tumor regression in UM PDXs [<xref rid="B58-cancers-11-00846" ref-type="bibr">58</xref>]. These studies suggest new potential combinational therapies for metastatic UM.</p><p>The Hippo oncosuppressor pathway limits organ size through a kinase cascade involving serine/threonine kinase 4 (MST1/2) and Large Tumor Suppressor Kinase 1/2 (LATS1/2 kinases) [<xref rid="B59-cancers-11-00846" ref-type="bibr">59</xref>]. The LATS1/2 kinases inactivate by phosphorylating YAP and Transcriptional Co-Activator With PDZ-Binding Motif (TAZ), which have oncogenic potential related to their ability to co-activate gene transcription. Indeed, high YAP/TAZ expression and nuclear localization has been found in several tumor types [<xref rid="B60-cancers-11-00846" ref-type="bibr">60</xref>,<xref rid="B61-cancers-11-00846" ref-type="bibr">61</xref>,<xref rid="B62-cancers-11-00846" ref-type="bibr">62</xref>,<xref rid="B63-cancers-11-00846" ref-type="bibr">63</xref>], including UM [<xref rid="B64-cancers-11-00846" ref-type="bibr">64</xref>,<xref rid="B65-cancers-11-00846" ref-type="bibr">65</xref>]. Mutation-activated G&#x003b1;Q or G&#x003b1;11 induced YAP/TAZ dephosphorylation and signaling, which is an essential mediator of oncogenic activity in UM development. The activation of YAP by activated G&#x003b1;Q involves a Trio-Rho/Rac signaling circuit, which stimulates actin polymerization independently upon the activation of PLC&#x003b2; and the Hippo pathway [<xref rid="B65-cancers-11-00846" ref-type="bibr">65</xref>]. Knockdown of mutated G&#x003b1;Q decreased the nuclear localization of YAP and its interaction with the transcription factor TEA domain transcription factor (TEAD) [<xref rid="B65-cancers-11-00846" ref-type="bibr">65</xref>], which is essential for YAP-mediated proliferation, epithelial&#x02013;mesenchymal transition, and oncogenesis [<xref rid="B66-cancers-11-00846" ref-type="bibr">66</xref>]. Moreover, the YAP inhibitor verteporfin, inhibited the growth and tumorigenesis of G&#x003b1;Q/11-mutated UM cells [<xref rid="B64-cancers-11-00846" ref-type="bibr">64</xref>,<xref rid="B65-cancers-11-00846" ref-type="bibr">65</xref>,<xref rid="B67-cancers-11-00846" ref-type="bibr">67</xref>]. Altogether, these data indicate that YAP is a potentially useful target for the therapy of UM-bearing mutations in <italic>GNAQ</italic> or <italic>GNA11</italic> genes [<xref rid="B68-cancers-11-00846" ref-type="bibr">68</xref>,<xref rid="B69-cancers-11-00846" ref-type="bibr">69</xref>].</p><p>A recent study showed that G&#x003b1;Q activates the focal adhesion kinase Focal adhesion kinase (FAK), whose activity is essential for YAP activation and UM cell growth. Ablation of the FAK-encoding gene (<italic>PTK2</italic>) or blockade of FAK activity by the small molecules VS-4718 or PF562771 inhibits YAP signaling and UM growth [<xref rid="B70-cancers-11-00846" ref-type="bibr">70</xref>], suggesting that FAK is a new actionable target in UM and for other G&#x003b1;Q-dependent diseases.</p></sec><sec id="sec4-cancers-11-00846"><title>4. Targeting Chromatin Structure and Transcription</title><p>The transcriptional programs that mediate tumor progression require changes in the expression or function of transcription factors and several chromatin structure regulators [<xref rid="B71-cancers-11-00846" ref-type="bibr">71</xref>]. In UM, which typically has a low mutational burden [<xref rid="B16-cancers-11-00846" ref-type="bibr">16</xref>], epigenetics alterations, including changes in the DNA methylation or histone acetylation status, may play a relevant pathogenic role [<xref rid="B72-cancers-11-00846" ref-type="bibr">72</xref>,<xref rid="B73-cancers-11-00846" ref-type="bibr">73</xref>]. Therefore, the targeting of transcriptional regulators may represent an attractive therapeutic option in UM.</p><p>Histone deacetylases (HDAC) are a family of enzymes that remove acetyl groups from acetylated lysine residues of histone proteins and act as epigenetic regulators. In general, deacetylated histones can bind to the DNA more tightly, thus limiting the access of transcription factors and repressing gene transcription. On the other hand, histone acetylation is associated with gene transcription. Human HDACs are divided into four classes, displaying different sensitivity to synthetic inhibitors, and play a relevant role as epigenetic modifiers in cancer [<xref rid="B74-cancers-11-00846" ref-type="bibr">74</xref>]. In UM, several HDAC inhibitors, including valproic acid, panobinostat, vorinostat [<xref rid="B75-cancers-11-00846" ref-type="bibr">75</xref>], tricostatin A [<xref rid="B75-cancers-11-00846" ref-type="bibr">75</xref>,<xref rid="B76-cancers-11-00846" ref-type="bibr">76</xref>], tenovin-6 [<xref rid="B77-cancers-11-00846" ref-type="bibr">77</xref>], depsipeptide [<xref rid="B78-cancers-11-00846" ref-type="bibr">78</xref>], MS-275 [<xref rid="B79-cancers-11-00846" ref-type="bibr">79</xref>], quisinostat [<xref rid="B80-cancers-11-00846" ref-type="bibr">80</xref>], JSL-1 [<xref rid="B81-cancers-11-00846" ref-type="bibr">81</xref>], MC1568, and MCI1575 [<xref rid="B82-cancers-11-00846" ref-type="bibr">82</xref>], have shown antitumor activities, including growth arrest or apoptosis in vitro and/or suppression of UM xenograft growth [<xref rid="B83-cancers-11-00846" ref-type="bibr">83</xref>]. Interestingly, some of these HDAC inhibitors induce a shift of the gene expression profile from a high-risk (class-2) to a low-risk (class-1) profile in primary UM cell cultures [<xref rid="B75-cancers-11-00846" ref-type="bibr">75</xref>]. A recent report showed additive cytotoxic effects by combining neratinib (an inhibitor of Her2 and Epidermal Growth Factor Receptor (EGFR) tyrosine kinases) with the HDAC inhibitor entinostat in PDX of UM. This drug combination cooperatively induced the internalization and degradation of G&#x003b1; proteins and EGFR and also targeted the Ras pathway, thereby activating mitochondrial dysfunction and autophagy [<xref rid="B84-cancers-11-00846" ref-type="bibr">84</xref>]. EGFR is frequently overexpressed in UM and has been proposed as a potential target [<xref rid="B85-cancers-11-00846" ref-type="bibr">85</xref>].</p><p>Based on the encouraging results of preclinical studies, clinical studies with HDAC inhibitors are ongoing. A phase 2 study of oral vorinostat in metastatic UM had the primary objective to determine the overall RR. It enrolled 23 patients and was terminated in 2018, but the results are not yet available (NCT01587352). A proof of concept study of vorinostat in patients with class 2 high-risk UM will assess the possible switch from a class 2 gene expression profile into a profile that resembles normal melanocytes on fine needle aspirate biopsies (NCT03022565) as observed for cell lines treated with HDAC inhibitors [<xref rid="B75-cancers-11-00846" ref-type="bibr">75</xref>]. A randomized phase 2 trial will assess the effects of adjuvant sunitinib or valproic acid in preventing high-risk UM from metastatic spreading by evaluating OS at 2 years (NCT02068586). A multicenter phase 2 open label study has been planned to evaluate efficacy of the concomitant use of the anti-PD1 pembrolizumab and entinostat in patients with metastatic UM (NCT02697630). The rationale for this study relies not only on the direct effect of HDAC inhibitors on UM cells, but also on their immune-modulatory activity, which may cooperate with the anti-PD-1 effects [<xref rid="B86-cancers-11-00846" ref-type="bibr">86</xref>]. </p><p>Alterations of DNA methylation represent another important epigenetic mechanism of cancer development [<xref rid="B87-cancers-11-00846" ref-type="bibr">87</xref>]. In general, gene promoter hypermethylation may induce silencing of oncosuppressor genes. These mechanisms can be a target for epigenetic therapy with drugs such as azacitidine and its derivatives that inhibit DNA methyltransferase I and mediate hypomethylation of DNA. On the other hand, hypomethylation has also been implicated in the development and progression of cancer through the activation of oncogene expression. Examples of genes silenced by hypermethylation in UM are <italic>INK4a</italic> [<xref rid="B88-cancers-11-00846" ref-type="bibr">88</xref>,<xref rid="B89-cancers-11-00846" ref-type="bibr">89</xref>], <italic>TIMP3</italic> [<xref rid="B90-cancers-11-00846" ref-type="bibr">90</xref>], and <italic>S100A2</italic> [<xref rid="B91-cancers-11-00846" ref-type="bibr">91</xref>]. The re-expression of these genes can be induced by in vitro treatment with azacitidine or its derivatives. In addition, treatment with demethylating agents may reduce the growth and invasiveness [<xref rid="B92-cancers-11-00846" ref-type="bibr">92</xref>] or enhance the sensitivity of UM cells to the cytotoxic activity of IFN-&#x003b3; in vitro [<xref rid="B91-cancers-11-00846" ref-type="bibr">91</xref>].</p><p>A recent study using a multiplatform analysis of 80 primary UM found that <italic>BAP1</italic> loss follows monosomy 3 in poor-prognosis cases and correlates with a peculiar global DNA methylation profile. Instead, a better-prognosis monosomy 3 cohort bearing <italic>EIF1AX</italic>- and <italic>SRSF2/SF3B1</italic>-mutant UM showed a distinct DNA methylation profile [<xref rid="B16-cancers-11-00846" ref-type="bibr">16</xref>]. Another study performed on 87 UM samples revealed phylogenetic clusters of global DNA methylation that correlated with the gene expression profile (class-1 versus class-2) and with <italic>BAP1</italic>, <italic>SF3B1</italic> or <italic>EIF1AX</italic> mutations [<xref rid="B93-cancers-11-00846" ref-type="bibr">93</xref>]. Altogether, these studies indicate that the global methylation profile is related to the almost mutually exclusive mutations in <italic>BAP1</italic>, <italic>SF3B1</italic> or <italic>EIF1AX</italic> genes, which are associated with a distinct metastatic risk. Therefore, the DNA methylation status may be important to modulate the metastatic behavior in UM, and drugs altering the DNA methylation profile may deserve further studies in high-risk UM, particularly in an adjuvant setting.</p><p>BRCA1 associated protein 1 (BAP1) has a histone deubiquitinase activity, which results in tumor and metastasis suppressor activity. A recent study used the transposase-directed transposon insertion to map the BAP1 target genes in UM. This &#x0201c;calling card technique&#x0201d; allowed generating a list of BAP1 genomic targets that provides new insights into pathways leading to UM metastasis and novel potential therapeutic targets [<xref rid="B94-cancers-11-00846" ref-type="bibr">94</xref>]. For example, the genes involved in the epithelial-to-mesenchymal transition signature were upregulated.</p><p>Among regulators of gene transcription, the bromodomain and extraterminal (BET) protein family members bromodomain containing 2, 3, 4 (BRD2, BRD3, BRD4) and Bromodomain Testis Associated (BRDT) promote transcriptional elongation by binding to acetylated lysine of histones in chromatin and recruiting transcriptional protein complexes. Pharmacological inhibitors of these proteins suppress the growth of different tumors and may represent potential anticancer drugs [<xref rid="B95-cancers-11-00846" ref-type="bibr">95</xref>,<xref rid="B96-cancers-11-00846" ref-type="bibr">96</xref>]. </p><p>In particular, the BRD4 inhibitor JQ1 [<xref rid="B97-cancers-11-00846" ref-type="bibr">97</xref>] has shown cytotoxic activity in UM cells bearing <italic>GNAQ/11</italic> mutations, while it had limited effects in unmutated cells. JQ1 inhibits the expression of genes involved in the regulation of cell cycle, apoptosis, and DNA repair, such as <italic>BCL-XL</italic> and <italic>RAD51.</italic> JQ1 was also effective in mouse xenograft models of <italic>GNAQ</italic>-mutant UM, supporting the concept that BRD4 targeting is a novel therapeutic possibility [<xref rid="B98-cancers-11-00846" ref-type="bibr">98</xref>].</p><p>As JQ1 has a short half-life and was not suitable for clinical trials, the second-generation BET inhibitor PLX51107 [<xref rid="B99-cancers-11-00846" ref-type="bibr">99</xref>] is now undergoing clinical testing in patients with different advanced cancers, including UM patients (NCT02683395). So far, however, patients with liver metastases of UM showed resistance to BET inhibitors and progressed following treatment. A very recent report addressed the mechanisms of metastasis resistance to BET inhibitors by focusing on soluble factors in the liver microenvironment [<xref rid="B100-cancers-11-00846" ref-type="bibr">100</xref>]. Fibroblast growth factor 2 (FGF2), which is produced by hepatic stellate cells, reduced the responsiveness of UM cells to the antiproliferative effect of BET inhibitors. In addition, treatment with BET inhibitors increased expression of the FGFR pathway in vitro and in UM patients. The combination of the FGFR inhibitor AZD4547 with PLX51107 inhibited the growth of UM cells co-implanted with human stellate cells in immune-deficient mice. These data provide the basis for new combinational treatments of UM liver metastases through the concomitant inhibition of BRD4 and FGFR pathways [<xref rid="B100-cancers-11-00846" ref-type="bibr">100</xref>].</p><p>A study of kinome expression profiling in JQ1-treated UM cells identified a repressed kinase network, comprising several cell cycle-regulated protein kinases. Accordingly, UM cells were sensitive to inhibitors of these protein kinases, including the PLK1 inhibitor BI6727 (volasertib). Therefore PLK1, and possibly other mitotic kinases, may represent new potential drug targets in UM [<xref rid="B101-cancers-11-00846" ref-type="bibr">101</xref>].</p></sec><sec id="sec5-cancers-11-00846"><title>5. Targeting Hyper-Expressed Molecules Involved in Progression</title><p>Several studies of gene or protein expression led to the identification of molecules that are overexpressed in primary UM, which progressed to a metastatic disease. Some of these molecules have been functionally linked to pro-invasive properties of UM cells. For example, the analysis of the gene expression profiling of primary UM showed higher expression of the <italic>SDCBP</italic> gene (encoding for mda-9/syntenin). Gene silencing showed an important role of mda-9/syntenin in UM cell migration, invasion, and FAK activation, suggesting that mda-9/syntenin is involved in uveal melanoma progression and may represent a potential therapeutic target [<xref rid="B102-cancers-11-00846" ref-type="bibr">102</xref>]. Mda9/syntenin was identified as a prometastatic molecule in cutaneous melanoma [<xref rid="B103-cancers-11-00846" ref-type="bibr">103</xref>] and then in different tumors [<xref rid="B104-cancers-11-00846" ref-type="bibr">104</xref>]. It is a multidomain adaptor protein, which binds to different oncogenic signaling molecules through its PDZ1 and PDZ2 domains and mediates a pro-invasive behavior [<xref rid="B105-cancers-11-00846" ref-type="bibr">105</xref>]. Recent studies showed that peptide [<xref rid="B106-cancers-11-00846" ref-type="bibr">106</xref>] or small-molecule [<xref rid="B107-cancers-11-00846" ref-type="bibr">107</xref>] PDZ inhibitors block mda-9/syntenin functions and the invasiveness of different cancer cells, although they have not yet been tested in UM models.</p><p>Several matrix metalloproteinases (MMPs) are involved in invasiveness, angiogenesis, and progression of different tumors, including UM, through the degradation of extracellular matrix components [<xref rid="B108-cancers-11-00846" ref-type="bibr">108</xref>]. Early studies showed that MMP-2 [<xref rid="B109-cancers-11-00846" ref-type="bibr">109</xref>] and/or MMP-9 [<xref rid="B110-cancers-11-00846" ref-type="bibr">110</xref>,<xref rid="B111-cancers-11-00846" ref-type="bibr">111</xref>] are expressed in primary UM, and high expressions correlate with a dismal prognosis. Further experimental evidence indicated that MMPs mediate UM cell invasiveness in vitro [<xref rid="B112-cancers-11-00846" ref-type="bibr">112</xref>] and in xenograft models. Indeed, inhibition of MMP2 expression and/or activity by epigallocatechin gallate [<xref rid="B113-cancers-11-00846" ref-type="bibr">113</xref>] or zeaxanthin [<xref rid="B114-cancers-11-00846" ref-type="bibr">114</xref>] inhibited UM cell invasiveness, supporting a potential role of MMP2 inhibitors in the prevention of UM metastases. </p><p>Membrane localization of MMP14 is induced by protein tyrosine phosphatase 4A3 (PTP4A3). Inhibition of MMP14 expression decreased UM cell invasiveness, suggesting that PTP4A3-mediated localization of MMP14 is relevant for metastasis induction [<xref rid="B115-cancers-11-00846" ref-type="bibr">115</xref>]. </p><p>The expression of a disintegrin and metalloproteinase <italic>(ADAM)10</italic> gene [<xref rid="B116-cancers-11-00846" ref-type="bibr">116</xref>] or protein [<xref rid="B117-cancers-11-00846" ref-type="bibr">117</xref>] in primary UM correlated with metastasis development and a poor survival. In addition, <italic>ADAM10</italic> silencing inhibits UM cell invasion in vitro, indicating that ADAM10 may contribute to UM progression and may represent a potential target for adjuvant therapy [<xref rid="B116-cancers-11-00846" ref-type="bibr">116</xref>]. </p><p>Notwithstanding our increasing knowledge on the role of metalloproteinases in tumor progression, the enthusiasm for MMP/ADAM inhibitors as anticancer agents has been weakened by the results of early clinical trials of broad-spectrum MMPs inhibitors. Novel drug-design strategies may allow the development of more specific MMPs or ADAM inhibitors suitable for future clinical studies [<xref rid="B118-cancers-11-00846" ref-type="bibr">118</xref>]. In this regard, MMP/ADAM inhibitors should be preferably tested in an adjuvant setting.</p><p>The tyrosine kinase receptor c-Met and its ligand hepatocyte growth factor (HGF) mediate proliferation, survival, and pro-invasive activity of several tumors [<xref rid="B119-cancers-11-00846" ref-type="bibr">119</xref>] including UM [<xref rid="B120-cancers-11-00846" ref-type="bibr">120</xref>]. <italic>MET</italic> mRNA [<xref rid="B116-cancers-11-00846" ref-type="bibr">116</xref>] or protein [<xref rid="B121-cancers-11-00846" ref-type="bibr">121</xref>,<xref rid="B122-cancers-11-00846" ref-type="bibr">122</xref>,<xref rid="B123-cancers-11-00846" ref-type="bibr">123</xref>] expression in primary UM correlates with a higher incidence of metastases, and UM liver metastases strongly express c-Met [<xref rid="B124-cancers-11-00846" ref-type="bibr">124</xref>]. In addition, soluble c-Met ectodomain increased in the sera of UM patients with liver metastases relative to patients without metastases, thus representing a potential biomarker of progression [<xref rid="B125-cancers-11-00846" ref-type="bibr">125</xref>]. Crizotinib, an inhibitor of c-Met, Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK), and ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS1), inhibited the phosphorylation of c-Met, suppressed in vitro migration of UM cells, and reduced metastasis formation in UM xenograft models [<xref rid="B126-cancers-11-00846" ref-type="bibr">126</xref>]. These data suggested crizotinib as an adjuvant therapy for UM patients at high risk of metastases. Therefore, a phase 2 clinical trial of crizotinib has been designed but is not yet recruiting, in high-risk UM following therapy of the primary tumor (NCT02223819).</p><p>The IGF-1R has been also implicated in UM progression, as IGF1-R is expressed in UM metastases. Both endogenously produced or exogenous IGF-1-mediated AKT phosphorylation and proliferation of a UM cell line derived from a metastasis and an anti-IGF-1R blocking mAb inhibited these effects [<xref rid="B127-cancers-11-00846" ref-type="bibr">127</xref>]. Moreover, two independent studies showed that the cyclolignan picropodophyllin, an inhibitor of IGF-1R, suppresses the growth of UM cells in vitro and in xenograft models [<xref rid="B128-cancers-11-00846" ref-type="bibr">128</xref>,<xref rid="B129-cancers-11-00846" ref-type="bibr">129</xref>]. Altogether, these studies support the potential benefit of IGF-1 or IGF-1R blockade in UM therapy.</p><p>Anti-angiogenic therapy is currently used for the treatment of metastases of several malignancies, in combination with other therapies. Angiogenesis may represent a potential target for therapy also in UM [<xref rid="B130-cancers-11-00846" ref-type="bibr">130</xref>], which is highly vascularized and expresses angiogenesis-related genes [<xref rid="B131-cancers-11-00846" ref-type="bibr">131</xref>]. Early observations reported increased concentrations of Vascular Endothelial Growth Factor A VEGF-A in aqueous humor in UM patients [<xref rid="B132-cancers-11-00846" ref-type="bibr">132</xref>]. In addition, VEGF-A is expressed by UM cells and is upregulated by hypoxia via HIF-1alpha [<xref rid="B133-cancers-11-00846" ref-type="bibr">133</xref>]. VEGF-A serum levels were higher in UM patients with metastases than in nonmetastatic ones, suggesting that VEGF-A could be involved in metastasis development [<xref rid="B133-cancers-11-00846" ref-type="bibr">133</xref>,<xref rid="B134-cancers-11-00846" ref-type="bibr">134</xref>]. Indeed, the anti-VEGF-A-blocking mAb bevacizumab inhibited in vitro invasion of UM cells and suppressed the formation of liver micrometastases in an experimental model in vivo [<xref rid="B135-cancers-11-00846" ref-type="bibr">135</xref>].</p><p>Local therapy with anti-angiogenic agents is broadly used for treating or preventing the complications of radiation therapy of primary UM. However, intravitreal bevacizumab in large primary UMs showed paradoxical tumor growth [<xref rid="B136-cancers-11-00846" ref-type="bibr">136</xref>]. In addition, in a preclinical model mimicking UM, intraocular injection of bevacizumab paradoxically stimulated melanoma growth in murine eyes, possibly due to the upregulation of pro-angiogenic factors [<xref rid="B137-cancers-11-00846" ref-type="bibr">137</xref>]. Altogether, these data suggest caution in the use of intravitreous bevacizumab for UM in the neoadjuvant setting.</p><p>Two studies of anti-angiogenic drugs addressed the treatment of metastatic UM. Aflibercept is a soluble VEGF receptor, which can trap VEGF and inhibit angiogenesis. A multicenter phase 2 study of aflibercept in patients with inoperable stage III or IV metastatic melanoma included ten patients with UM. This study reported a PFS of above 4 months in 50% of the UM cohort, suggesting potential activity [<xref rid="B138-cancers-11-00846" ref-type="bibr">138</xref>]. A phase 2 Trial of bevacizumab in combination with temozolomide as first-line treatment in patients with metastatic UM failed to reach the primary endpoint of 6-month PFR of 40% [<xref rid="B139-cancers-11-00846" ref-type="bibr">139</xref>]. </p><p>The overall modest effects of anti-VEGF/VEGFR therapies in metastatic UM may be explained by the activation of alternative pro-angiogenic pathways. A preclinical study showed that not only VEGF but also angiopoietin protein like-4 (ANGPTL4) was highly induced by hypoxia in UM cells and was present in vitreous samples from UM patients [<xref rid="B140-cancers-11-00846" ref-type="bibr">140</xref>]. Inhibition of either VEGF or ANGPTL4 alone reduced UM cell-driven angiogenesis in vitro, but the inhibition of both angiogenic factors showed additive effects. Therefore, co-targeting of both VEGF and ANGPTL4 may be required to block angiogenesis in UM. Moreover, the UM microenvironment can use IL-8 as an additional pro-angiogenic pathway [<xref rid="B141-cancers-11-00846" ref-type="bibr">141</xref>]. Signaling through HGF/MET may also cause resistance to anti-VEGF therapies [<xref rid="B142-cancers-11-00846" ref-type="bibr">142</xref>], and the simultaneous inhibition of VEGFR and MET results in enhanced efficacy [<xref rid="B143-cancers-11-00846" ref-type="bibr">143</xref>]. Cabozantinib (XL184; Exelixis, Inc.) is a multi-tyrosine kinase inhibitor that co-targets MET, AXL Receptor Tyrosine Kinase (AXL), and VEGFRs. In a phase 2 randomized discontinuation trial of cabozantinib in metastatic melanoma, 13 of the 22 evaluable patients (59%) with UM showed a reduction of at least one target lesion. The median OS for the 23 patients with UM enrolled was 12.6 months, and the median PFS was 4.8 months with an overall disease control rate of 61%, suggestive of a potential activity of cabozantinib in UM [<xref rid="B143-cancers-11-00846" ref-type="bibr">143</xref>]. A phase 2 randomized study of cabozantinib compared with temozolomide or dacarbazine in patients with metastatic UM has been completed, but results are not yet available (NCT01835145).</p><p>Another multikinase inhibitor, sunitinib, targets platelet-derived growth factor (PDGF)Rs, VEGFRs, and CD117 (c-KIT), which are expressed in the majority of metastatic UM. In a pilot trial, twenty patients with metastatic UM expressing c-KIT received daily sunitinib malate in 4-week cycles. There was one partial response and 12 stable diseases (SD), and the median OS and PFS were of 8.2 and 4.2 months, respectively. Intriguingly, no correlation between c-KIT expression and clinical outcome was found, suggesting the possible importance of other TK targets [<xref rid="B144-cancers-11-00846" ref-type="bibr">144</xref>]. Another study of adjuvant sunitinib compared OS in high-risk UM patients with a retrospective cohort of institutional controls with the same risk factors. In this trial, adjuvant sunitinib was associated with a better OS [<xref rid="B145-cancers-11-00846" ref-type="bibr">145</xref>]. </p><p>The multikinase inhibitor sorafenib, which targets VEGFR, PDGFR, and Raf kinases, was also tested in advanced UM. However, a clinical phase 2 study showed only disease stabilizations, significant toxicity, and no improvement of the quality of life [<xref rid="B146-cancers-11-00846" ref-type="bibr">146</xref>]. Further, the combination of sorafenib with carboplatin and paclitaxel (NCT00329641), showed only minor responses and stabilizations, without impact on survival [<xref rid="B43-cancers-11-00846" ref-type="bibr">43</xref>]. The ubiquitin-like protein NEDD8 (neural-precursor cell-expressed developmentally downregulated 8) is conjugated to different target proteins through a process called neddylation, by NEDD8 Activating Enzyme E1 Subunit 1, 2 (NAE1 and NAE2) enzymes. This process is similar to ubiquitination and has been involved in tumor progression and angiogenesis [<xref rid="B147-cancers-11-00846" ref-type="bibr">147</xref>]. A recent report showed that NAE1 is highly expressed in UM cells, and that blockade of neddylation by the small molecule MLN4924 inhibited the stem-cell phenotype, paracrine secretion of VEGF-C, and angiogenic properties in UM cells. Inhibition of neddylation suppressed the development of hepatic metastases in an UM xenograft model, suggesting that the neddylation pathway represents a new target for the prevention or treatment of metastasis in UM [<xref rid="B148-cancers-11-00846" ref-type="bibr">148</xref>].</p><p>Several lines of evidence indicated a possible role for the chemokine receptors CXCR4 and CCR7 in the metastatic progression of UM. CXCR4 protein expression was detected in a fraction of UM primary tumors, in relation to an epithelioid-mixed UM cell phenotype [<xref rid="B149-cancers-11-00846" ref-type="bibr">149</xref>]. In vitro studies showed that hypoxia increased migration and invasiveness of UM cells through the HIF-1&#x003b1;-dependent expression of chemokine receptor CXCR4 [<xref rid="B150-cancers-11-00846" ref-type="bibr">150</xref>]. An arylsulfonamide compound (64B) inhibits the hypoxia-inducible expression of <italic>MET</italic> and <italic>CXCR4</italic> and reduces primary UM growth and metastasis in xenograft models. The compound 64B interferes with HIF-1&#x003b1; binding to p300/CBP co-factors and inhibits p300 recruitment and activation of the <italic>MET</italic> and <italic>CXCR4</italic> gene promoters. A further optimization of the 64B scaffold may allow the development of new compounds for the UM treatment [<xref rid="B151-cancers-11-00846" ref-type="bibr">151</xref>]. An antibody blocking the CXCR4 ligand CXCL12 or siRNA targeting <italic>CXCR4</italic> expression [<xref rid="B152-cancers-11-00846" ref-type="bibr">152</xref>] inhibited migration of UM cells by liver extracts. In addition, a small molecule, partial antagonist of CXCR4, inhibited metastasis formation in different xenograft tumor models, including UM [<xref rid="B153-cancers-11-00846" ref-type="bibr">153</xref>].</p><p>More recent data indicate that <italic>CXCR4</italic> expression is epigenetically regulated in the tumor microenvironment [<xref rid="B154-cancers-11-00846" ref-type="bibr">154</xref>]. CCR7 expression in primary UM is associated with poor survival, suggesting that it may represent a target for therapy [<xref rid="B155-cancers-11-00846" ref-type="bibr">155</xref>]. Although UM cell lines express CXCR4 and CCR7, which are relevant for hepatic metastases formation, factors present in the hepatic microenvironment reduced CXCR4 and CCR7 expression on UM cells [<xref rid="B156-cancers-11-00846" ref-type="bibr">156</xref>].</p></sec><sec sec-type="conclusions" id="sec6-cancers-11-00846"><title>6. Conclusions</title><p>Metastatic UM still remains an incurable disease, since no therapies have shown a significant impact on survival so far [<xref rid="B1-cancers-11-00846" ref-type="bibr">1</xref>,<xref rid="B2-cancers-11-00846" ref-type="bibr">2</xref>,<xref rid="B3-cancers-11-00846" ref-type="bibr">3</xref>,<xref rid="B5-cancers-11-00846" ref-type="bibr">5</xref>]. In particular, the failure of MEK inhibitors to significantly improve survival [<xref rid="B45-cancers-11-00846" ref-type="bibr">45</xref>] may relate to the redundancy of signaling pathways downstream the mutated G&#x003b1; proteins. Therefore, combinational therapies that co-target multiple pathways are currently under investigation. Recent preclinical studies provided new chances of directly blocking mutated G&#x003b1; proteins activity and their downstream signaling pathways through the natural depsipeptide FR900359, which acts as an allosteric inhibitor of G&#x003b1; [<xref rid="B34-cancers-11-00846" ref-type="bibr">34</xref>]. However, FR900359 is active on both activation-mutated and nonmutated G&#x003b1; proteins [<xref rid="B33-cancers-11-00846" ref-type="bibr">33</xref>,<xref rid="B34-cancers-11-00846" ref-type="bibr">34</xref>], raising the question about potential side-effects. Another potentially interesting actionable target is ARF6, which is necessary for G&#x003b1; protein signaling through all downstream pathways [<xref rid="B44-cancers-11-00846" ref-type="bibr">44</xref>].</p><p>High-risk UM-bearing <italic>BAP1</italic> mutation and chromosome 3 monosomy displayed distinct epigenetic [<xref rid="B16-cancers-11-00846" ref-type="bibr">16</xref>] and gene expression profiles [<xref rid="B157-cancers-11-00846" ref-type="bibr">157</xref>,<xref rid="B158-cancers-11-00846" ref-type="bibr">158</xref>]. These findings indicate that modifiers of chromatin structure or gene transcription may represent useful tools to revert high-risk UM phenotype and inhibit aggressiveness. Preclinical studies using different HDAC [<xref rid="B83-cancers-11-00846" ref-type="bibr">83</xref>] or BET inhibitors [<xref rid="B98-cancers-11-00846" ref-type="bibr">98</xref>,<xref rid="B100-cancers-11-00846" ref-type="bibr">100</xref>] showed promising results in UM preclinical models, and several clinical trials are already ongoing. </p><p>Other potential targets are hyper-expressed molecules associated with UM metastatic behavior. Preclinical studies validated several of these molecules as potential targets for inhibiting UM invasiveness and metastatic progression. In several instances, however, preclinical UM models are hampered by the frequent usage of nonmonosomic cell lines, which are poorly representative of the high-risk UM. In this respect, the development of UM Patient Derived Xenograft (PDX) models, particularly from high-risk primary UM or from liver metastases [<xref rid="B159-cancers-11-00846" ref-type="bibr">159</xref>], may provide better preclinical tools for testing new therapies.</p><p>The possibility to identify high-risk patients through the assessment of monosomy 3, <italic>BAP1</italic> status or gene expression profiling opens up the possibility of testing agents inhibiting UM invasiveness and progression in an adjuvant setting. Strategies for the prevention of metastasis must consider that at the time of diagnosis, eventually life-threatening micrometastases have already formed. Therefore, a treatment inhibiting invasiveness will not have major therapeutic effects unless it also inhibits the growth of these micrometastases. In this respect, the hepatic microenvironment may contribute to the resistance of UM metastases to different treatments, as it provides multiple growth and survival factors to UM cells, including HGF, FGF2, IGF-1, and CXCL12. A recent study reported that several inflammatory and profibrogenic mediators are important in the homing of UM cells to the liver and are part of a bidirectional crosstalk between UM cells and hepatic stellate cells [<xref rid="B160-cancers-11-00846" ref-type="bibr">160</xref>]. It is hoped that a better knowledge of this metastatic microenvironment may provide new targets for UM therapy.</p></sec></body><back><ack><title>Acknowledgments</title><p>We wish to thank Dr. Mauro Mazzocut for his help in the preparation of the References. </p></ack><notes><title>Author Contributions</title><p>M.C. wrote part of the text and prepared <xref rid="cancers-11-00846-t001" ref-type="table">Table 1</xref>; S.F. wrote part of the text and prepared <xref ref-type="fig" rid="cancers-11-00846-f001">Figure 1</xref>; U.P. wrote part of the text and reviewed the manuscript; R.G. organized and reviewed the manuscript and wrote part of the text.</p></notes><notes><title>Funding</title><p>The Associazione Italiana per la Ricerca sul Cancro (AIRC, IG 17103), the Compagnia di San Paolo (#20067) and the Italian Ministry of Health, 5 &#x000d7; 1000 funds 2016 to UP, and 5 &#x000d7; 1000 funds 2014 to SF are acknowledged.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors have no conflict of interest to declare.</p></notes><ref-list><title>References</title><ref id="B1-cancers-11-00846"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Manson</surname><given-names>D.K.</given-names></name><name><surname>Marr</surname><given-names>B.P.</given-names></name><name><surname>Carvajal</surname><given-names>R.D.</given-names></name></person-group><article-title>Treatment of uveal melanoma: Where are we now?</article-title><source>Ther. Adv. Med. Oncol.</source><year>2018</year><fpage>10</fpage><pub-id pub-id-type="doi">10.1177/1758834018757175</pub-id><pub-id pub-id-type="pmid">29497459</pub-id></element-citation></ref><ref id="B2-cancers-11-00846"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>K.K.</given-names></name><name><surname>Bollin</surname><given-names>K.B.</given-names></name><name><surname>Patel</surname><given-names>S.P.</given-names></name></person-group><article-title>Obstacles to improving outcomes in the treatment of uveal melanoma</article-title><source>Cancer</source><year>2018</year><volume>124</volume><fpage>2693</fpage><lpage>2703</lpage><pub-id pub-id-type="doi">10.1002/cncr.31284</pub-id><pub-id pub-id-type="pmid">29579316</pub-id></element-citation></ref><ref id="B3-cancers-11-00846"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>J.J.</given-names></name><name><surname>Diefenbach</surname><given-names>R.J.</given-names></name><name><surname>Joshua</surname><given-names>A.M.</given-names></name><name><surname>Kefford</surname><given-names>R.F.</given-names></name><name><surname>Carlino</surname><given-names>M.S.</given-names></name><name><surname>Rizos</surname><given-names>H.</given-names></name></person-group><article-title>Oncogenic signaling in uveal melanoma</article-title><source>Pigment Cell Melanoma Res.</source><year>2018</year><volume>31</volume><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12708</pub-id><pub-id pub-id-type="pmid">29738114</pub-id></element-citation></ref><ref id="B4-cancers-11-00846"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>J.J.</given-names></name><name><surname>Flaherty</surname><given-names>K.T.</given-names></name><name><surname>Ribas</surname><given-names>A.</given-names></name><name><surname>Long</surname><given-names>G.V.</given-names></name></person-group><article-title>Targeted agents and immunotherapies: Optimizing outcomes in melanoma</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>463</fpage><lpage>482</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2017.43</pub-id><pub-id pub-id-type="pmid">28374786</pub-id></element-citation></ref><ref id="B5-cancers-11-00846"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rantala</surname><given-names>E.S.</given-names></name><name><surname>Hernberg</surname><given-names>M.</given-names></name><name><surname>Kivel&#x000e4;</surname><given-names>T.T.</given-names></name></person-group><article-title>Survival after treatment for metastatic uveal melanoma: A systematic review and meta-analysis</article-title><source>Melanoma Res.</source><year>2019</year><pub-id pub-id-type="doi">10.1097/CMR.0000000000000575</pub-id></element-citation></ref><ref id="B6-cancers-11-00846"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>C.D.</given-names></name><name><surname>Bezrookove</surname><given-names>V.</given-names></name><name><surname>Green</surname><given-names>G.</given-names></name><name><surname>Bauer</surname><given-names>J.</given-names></name><name><surname>Gaugler</surname><given-names>L.</given-names></name><name><surname>O&#x02019;Brien</surname><given-names>J.M.</given-names></name><name><surname>Simpson</surname><given-names>E.M.</given-names></name><name><surname>Barsh</surname><given-names>G.S.</given-names></name><name><surname>Bastian</surname><given-names>B.C.</given-names></name></person-group><article-title>Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi</article-title><source>Nature</source><year>2009</year><volume>457</volume><fpage>599</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/nature07586</pub-id><pub-id pub-id-type="pmid">19078957</pub-id></element-citation></ref><ref id="B7-cancers-11-00846"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Raamsdonk</surname><given-names>C.D.</given-names></name><name><surname>Griewank</surname><given-names>K.G.</given-names></name><name><surname>Crosby</surname><given-names>M.B.</given-names></name><name><surname>Garrido</surname><given-names>M.C.</given-names></name><name><surname>Vemula</surname><given-names>S.</given-names></name><name><surname>Wiesner</surname><given-names>T.</given-names></name><name><surname>Obenauf</surname><given-names>A.C.</given-names></name><name><surname>Wackernagel</surname><given-names>W.</given-names></name><name><surname>Green</surname><given-names>G.</given-names></name><name><surname>Bouvier</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Mutations in GNA11 in uveal melanoma</article-title><source>N. Engl. J. Med.</source><year>2010</year><volume>363</volume><fpage>2191</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1000584</pub-id><pub-id pub-id-type="pmid">21083380</pub-id></element-citation></ref><ref id="B8-cancers-11-00846"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>P.</given-names></name><name><surname>Aoude</surname><given-names>L.G.</given-names></name><name><surname>Wadt</surname><given-names>K.</given-names></name><name><surname>Glasson</surname><given-names>W.J.</given-names></name><name><surname>Warrier</surname><given-names>S.K.</given-names></name><name><surname>Hewitt</surname><given-names>A.W.</given-names></name><name><surname>Kiilgaard</surname><given-names>J.F.</given-names></name><name><surname>Heegaard</surname><given-names>S.</given-names></name><name><surname>Isaacs</surname><given-names>T.</given-names></name><name><surname>Franchina</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>4624</fpage><lpage>4631</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6614</pub-id><pub-id pub-id-type="pmid">26683228</pub-id></element-citation></ref><ref id="B9-cancers-11-00846"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>A.R.</given-names></name><name><surname>Ceraudo</surname><given-names>E.</given-names></name><name><surname>Sher</surname><given-names>J.J.</given-names></name><name><surname>Guan</surname><given-names>Y.</given-names></name><name><surname>Shoushtari</surname><given-names>A.N.</given-names></name><name><surname>Chang</surname><given-names>M.T.</given-names></name><name><surname>Zhang</surname><given-names>J.Q.</given-names></name><name><surname>Walczak</surname><given-names>E.G.</given-names></name><name><surname>Kazmi</surname><given-names>M.A.</given-names></name><name><surname>Taylor</surname><given-names>B.S.</given-names></name><etal/></person-group><article-title>Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma</article-title><source>Nat. Genet.</source><year>2016</year><volume>48</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.1038/ng.3549</pub-id><pub-id pub-id-type="pmid">27089179</pub-id></element-citation></ref><ref id="B10-cancers-11-00846"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horsman</surname><given-names>D.E.</given-names></name><name><surname>Sroka</surname><given-names>H.</given-names></name><name><surname>Rootman</surname><given-names>J.</given-names></name><name><surname>White</surname><given-names>V.A.</given-names></name></person-group><article-title>Monosomy 3 and isochromosome 8q in a uveal melanoma</article-title><source>Cancer Genet. Cytogenet.</source><year>1990</year><volume>45</volume><fpage>249</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/0165-4608(90)90090-W</pub-id><pub-id pub-id-type="pmid">2317773</pub-id></element-citation></ref><ref id="B11-cancers-11-00846"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescher</surname><given-names>G.</given-names></name><name><surname>Bornfeld</surname><given-names>N.</given-names></name><name><surname>Becher</surname><given-names>R.</given-names></name></person-group><article-title>Nonrandom chromosomal abnormalities in primary uveal melanoma</article-title><source>J. Natl. Cancer Inst.</source><year>1990</year><volume>82</volume><fpage>1765</fpage><lpage>1769</lpage><pub-id pub-id-type="doi">10.1093/jnci/82.22.1765</pub-id><pub-id pub-id-type="pmid">2231772</pub-id></element-citation></ref><ref id="B12-cancers-11-00846"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prescher</surname><given-names>G.</given-names></name><name><surname>Bornfeld</surname><given-names>N.</given-names></name><name><surname>Hirche</surname><given-names>H.</given-names></name><name><surname>Horsthemke</surname><given-names>B.</given-names></name><name><surname>J&#x000f6;ckel</surname><given-names>K.H.</given-names></name><name><surname>Becher</surname><given-names>R.</given-names></name></person-group><article-title>Prognostic implications of monosomy 3 in uveal melanoma</article-title><source>Lancet</source><year>1996</year><volume>347</volume><fpage>1222</fpage><lpage>1225</lpage><pub-id pub-id-type="pmid">8622452</pub-id></element-citation></ref><ref id="B13-cancers-11-00846"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Worley</surname><given-names>L.A.</given-names></name><name><surname>Person</surname><given-names>E.</given-names></name><name><surname>Char</surname><given-names>D.H.</given-names></name><name><surname>Bowcock</surname><given-names>A.M.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>2923</fpage><lpage>2927</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-06-2383</pub-id><pub-id pub-id-type="pmid">17504992</pub-id></element-citation></ref><ref id="B14-cancers-11-00846"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbour</surname><given-names>J.W.</given-names></name><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Roberson</surname><given-names>E.D.O.</given-names></name><name><surname>Duan</surname><given-names>S.</given-names></name><name><surname>Cao</surname><given-names>L.</given-names></name><name><surname>Worley</surname><given-names>L.A.</given-names></name><name><surname>Council</surname><given-names>M.L.</given-names></name><name><surname>Matatall</surname><given-names>K.A.</given-names></name><name><surname>Helms</surname><given-names>C.</given-names></name><name><surname>Bowcock</surname><given-names>A.M.</given-names></name></person-group><article-title>Frequent mutation of BAP1 in metastasizing uveal melanomas</article-title><source>Science</source><year>2010</year><volume>330</volume><fpage>1410</fpage><lpage>1413</lpage><pub-id pub-id-type="doi">10.1126/science.1194472</pub-id><pub-id pub-id-type="pmid">21051595</pub-id></element-citation></ref><ref id="B15-cancers-11-00846"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>M.</given-names></name><name><surname>Ma&#x000df;h&#x000f6;fer</surname><given-names>L.</given-names></name><name><surname>Temming</surname><given-names>P.</given-names></name><name><surname>Rahmann</surname><given-names>S.</given-names></name><name><surname>Metz</surname><given-names>C.</given-names></name><name><surname>Bornfeld</surname><given-names>N.</given-names></name><name><surname>van de Nes</surname><given-names>J.</given-names></name><name><surname>Klein-Hitpass</surname><given-names>L.</given-names></name><name><surname>Hinnebusch</surname><given-names>A.G.</given-names></name><name><surname>Horsthemke</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3</article-title><source>Nat. Genet.</source><year>2013</year><volume>45</volume><fpage>933</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1038/ng.2674</pub-id><pub-id pub-id-type="pmid">23793026</pub-id></element-citation></ref><ref id="B16-cancers-11-00846"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robertson</surname><given-names>A.G.</given-names></name><name><surname>Shih</surname><given-names>J.</given-names></name><name><surname>Yau</surname><given-names>C.</given-names></name><name><surname>Gibb</surname><given-names>E.A.</given-names></name><name><surname>Oba</surname><given-names>J.</given-names></name><name><surname>Mungall</surname><given-names>K.L.</given-names></name><name><surname>Hess</surname><given-names>J.M.</given-names></name><name><surname>Uzunangelov</surname><given-names>V.</given-names></name><name><surname>Walter</surname><given-names>V.</given-names></name><name><surname>Danilova</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma</article-title><source>Cancer Cell</source><year>2017</year><volume>32</volume><fpage>204</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2017.07.003</pub-id><pub-id pub-id-type="pmid">28810145</pub-id></element-citation></ref><ref id="B17-cancers-11-00846"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akbani</surname><given-names>R.</given-names></name><name><surname>Akdemir</surname><given-names>K.C.</given-names></name><name><surname>Aksoy</surname><given-names>B.A.</given-names></name><name><surname>Albert</surname><given-names>M.</given-names></name><name><surname>Ally</surname><given-names>A.</given-names></name><name><surname>Amin</surname><given-names>S.B.</given-names></name><name><surname>Arachchi</surname><given-names>H.</given-names></name><name><surname>Arora</surname><given-names>A.</given-names></name><name><surname>Auman</surname><given-names>J.T.</given-names></name><name><surname>Ayala</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Cancer Genome Atlas Network Genomic Classification of Cutaneous Melanoma</article-title><source>Cell</source><year>2015</year><volume>161</volume><fpage>1681</fpage><lpage>1696</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.05.044</pub-id><pub-id pub-id-type="pmid">26091043</pub-id></element-citation></ref><ref id="B18-cancers-11-00846"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Snyder</surname><given-names>A.</given-names></name><name><surname>Makarov</surname><given-names>V.</given-names></name><name><surname>Merghoub</surname><given-names>T.</given-names></name><name><surname>Yuan</surname><given-names>J.</given-names></name><name><surname>Zaretsky</surname><given-names>J.M.</given-names></name><name><surname>Desrichard</surname><given-names>A.</given-names></name><name><surname>Walsh</surname><given-names>L.A.</given-names></name><name><surname>Postow</surname><given-names>M.A.</given-names></name><name><surname>Wong</surname><given-names>P.</given-names></name><name><surname>Ho</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Genetic basis for clinical response to CTLA-4 blockade in melanoma</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>2189</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmid">25409260</pub-id></element-citation></ref><ref id="B19-cancers-11-00846"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Allen</surname><given-names>E.M.</given-names></name><name><surname>Miao</surname><given-names>D.</given-names></name><name><surname>Schilling</surname><given-names>B.</given-names></name><name><surname>Shukla</surname><given-names>S.A.</given-names></name><name><surname>Blank</surname><given-names>C.</given-names></name><name><surname>Zimmer</surname><given-names>L.</given-names></name><name><surname>Sucker</surname><given-names>A.</given-names></name><name><surname>Hillen</surname><given-names>U.</given-names></name><name><surname>Foppen</surname><given-names>M.H.G.</given-names></name><name><surname>Goldinger</surname><given-names>S.M.</given-names></name><etal/></person-group><article-title>Genomic correlates of response to CTLA-4 blockade in metastatic melanoma</article-title><source>Science</source><year>2015</year><volume>350</volume><fpage>207</fpage><lpage>211</lpage><pub-id pub-id-type="doi">10.1126/science.aad0095</pub-id><pub-id pub-id-type="pmid">26359337</pub-id></element-citation></ref><ref id="B20-cancers-11-00846"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danilova</surname><given-names>L.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Sunshine</surname><given-names>J.</given-names></name><name><surname>Kaunitz</surname><given-names>G.J.</given-names></name><name><surname>Cottrell</surname><given-names>T.R.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Esandrio</surname><given-names>J.</given-names></name><name><surname>Anders</surname><given-names>R.A.</given-names></name><name><surname>Cope</surname><given-names>L.</given-names></name><name><surname>Pardoll</surname><given-names>D.M.</given-names></name><etal/></person-group><article-title>Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2016</year><volume>113</volume><fpage>E7769</fpage><lpage>E7777</lpage><pub-id pub-id-type="doi">10.1073/pnas.1607836113</pub-id><pub-id pub-id-type="pmid">27837027</pub-id></element-citation></ref><ref id="B21-cancers-11-00846"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McGranahan</surname><given-names>N.</given-names></name><name><surname>Furness</surname><given-names>A.J.S.</given-names></name><name><surname>Rosenthal</surname><given-names>R.</given-names></name><name><surname>Ramskov</surname><given-names>S.</given-names></name><name><surname>Lyngaa</surname><given-names>R.</given-names></name><name><surname>Saini</surname><given-names>S.K.</given-names></name><name><surname>Jamal-Hanjani</surname><given-names>M.</given-names></name><name><surname>Wilson</surname><given-names>G.A.</given-names></name><name><surname>Birkbak</surname><given-names>N.J.</given-names></name><name><surname>Hiley</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade</article-title><source>Science</source><year>2016</year><volume>351</volume><fpage>1463</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1126/science.aaf1490</pub-id><pub-id pub-id-type="pmid">26940869</pub-id></element-citation></ref><ref id="B22-cancers-11-00846"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heppt</surname><given-names>M.V.</given-names></name><name><surname>Steeb</surname><given-names>T.</given-names></name><name><surname>Schlager</surname><given-names>J.G.</given-names></name><name><surname>Rosumeck</surname><given-names>S.</given-names></name><name><surname>Dressler</surname><given-names>C.</given-names></name><name><surname>Ruzicka</surname><given-names>T.</given-names></name><name><surname>Nast</surname><given-names>A.</given-names></name><name><surname>Berking</surname><given-names>C.</given-names></name></person-group><article-title>Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review</article-title><source>Cancer Treat. Rev.</source><year>2017</year><volume>60</volume><fpage>44</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2017.08.009</pub-id><pub-id pub-id-type="pmid">28881222</pub-id></element-citation></ref><ref id="B23-cancers-11-00846"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mignard</surname><given-names>C.</given-names></name><name><surname>Deschamps Huvier</surname><given-names>A.</given-names></name><name><surname>Gillibert</surname><given-names>A.</given-names></name><name><surname>Duval Modeste</surname><given-names>A.B.</given-names></name><name><surname>Dutriaux</surname><given-names>C.</given-names></name><name><surname>Khammari</surname><given-names>A.</given-names></name><name><surname>Avril</surname><given-names>M.-F.</given-names></name><name><surname>Kramkimel</surname><given-names>N.</given-names></name><name><surname>Mortier</surname><given-names>L.</given-names></name><name><surname>Marcant</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma</article-title><source>J. Oncol.</source><year>2018</year><volume>2018</volume><fpage>1908065</fpage><pub-id pub-id-type="doi">10.1155/2018/1908065</pub-id><pub-id pub-id-type="pmid">30631354</pub-id></element-citation></ref><ref id="B24-cancers-11-00846"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaro</surname><given-names>A.</given-names></name><name><surname>Gangemi</surname><given-names>R.</given-names></name><name><surname>Piaggio</surname><given-names>F.</given-names></name><name><surname>Angelini</surname><given-names>G.</given-names></name><name><surname>Barisione</surname><given-names>G.</given-names></name><name><surname>Ferrini</surname><given-names>S.</given-names></name><name><surname>Pfeffer</surname><given-names>U.</given-names></name></person-group><article-title>The biology of uveal melanoma</article-title><source>Cancer Metastasis Rev.</source><year>2017</year><volume>36</volume><fpage>109</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1007/s10555-017-9663-3</pub-id><pub-id pub-id-type="pmid">28229253</pub-id></element-citation></ref><ref id="B25-cancers-11-00846"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Worley</surname><given-names>L.A.</given-names></name><name><surname>Long</surname><given-names>M.D.</given-names></name><name><surname>Duan</surname><given-names>S.</given-names></name><name><surname>Council</surname><given-names>M.L.</given-names></name><name><surname>Bowcock</surname><given-names>A.M.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>Oncogenic mutations in GNAQ occur early in uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2008</year><volume>49</volume><fpage>5230</fpage><lpage>5234</lpage><pub-id pub-id-type="doi">10.1167/iovs.08-2145</pub-id><pub-id pub-id-type="pmid">18719078</pub-id></element-citation></ref><ref id="B26-cancers-11-00846"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bauer</surname><given-names>J.</given-names></name><name><surname>Kilic</surname><given-names>E.</given-names></name><name><surname>Vaarwater</surname><given-names>J.</given-names></name><name><surname>Bastian</surname><given-names>B.C.</given-names></name><name><surname>Garbe</surname><given-names>C.</given-names></name><name><surname>de Klein</surname><given-names>A.</given-names></name></person-group><article-title>Oncogenic GNAQ mutations are not correlated with disease-free survival in uveal melanoma</article-title><source>Br. J. Cancer</source><year>2009</year><volume>101</volume><fpage>813</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605226</pub-id><pub-id pub-id-type="pmid">19654573</pub-id></element-citation></ref><ref id="B27-cancers-11-00846"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>V.</given-names></name><name><surname>Lapadula</surname><given-names>D.</given-names></name><name><surname>Randolph</surname><given-names>C.</given-names></name><name><surname>Benovic</surname><given-names>J.L.</given-names></name><name><surname>Wedegaertner</surname><given-names>P.B.</given-names></name><name><surname>Aplin</surname><given-names>A.E.</given-names></name></person-group><article-title>Dysregulated GPCR Signaling and Therapeutic Options in Uveal Melanoma</article-title><source>Mol. Cancer Res.</source><year>2017</year><volume>15</volume><fpage>501</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-17-0007</pub-id><pub-id pub-id-type="pmid">28223438</pub-id></element-citation></ref><ref id="B28-cancers-11-00846"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Slater</surname><given-names>K.</given-names></name><name><surname>Hoo</surname><given-names>P.S.</given-names></name><name><surname>Buckley</surname><given-names>A.M.</given-names></name><name><surname>Piulats</surname><given-names>J.M.</given-names></name><name><surname>Villanueva</surname><given-names>A.</given-names></name><name><surname>Portela</surname><given-names>A.</given-names></name><name><surname>Kennedy</surname><given-names>B.N.</given-names></name></person-group><article-title>Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma</article-title><source>Cancer Metastasis Rev.</source><year>2018</year><volume>37</volume><fpage>335</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1007/s10555-018-9751-z</pub-id><pub-id pub-id-type="pmid">30094568</pub-id></element-citation></ref><ref id="B29-cancers-11-00846"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Musi</surname><given-names>E.</given-names></name><name><surname>Ho</surname><given-names>A.L.</given-names></name><name><surname>de Stanchina</surname><given-names>E.</given-names></name><name><surname>Schwartz</surname><given-names>G.K.</given-names></name></person-group><article-title>Inhibition of mutant GNAQ signaling in uveal melanoma induces AMPK-dependent autophagic cell death</article-title><source>Mol. Cancer Ther.</source><year>2013</year><volume>12</volume><fpage>768</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-1020</pub-id><pub-id pub-id-type="pmid">23443802</pub-id></element-citation></ref><ref id="B30-cancers-11-00846"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.</given-names></name><name><surname>Qiu</surname><given-names>C.</given-names></name><name><surname>Shang</surname><given-names>Q.</given-names></name><name><surname>Qian</surname><given-names>G.</given-names></name><name><surname>Fan</surname><given-names>X.</given-names></name><name><surname>Ge</surname><given-names>S.</given-names></name><name><surname>Jia</surname><given-names>R.</given-names></name></person-group><article-title>The oncolytic virus H101 combined with GNAQ siRNA-mediated knockdown reduces uveal melanoma cell viability</article-title><source>J. Cell. Biochem.</source><year>2019</year><volume>120</volume><fpage>5766</fpage><lpage>5776</lpage><pub-id pub-id-type="doi">10.1002/jcb.27863</pub-id><pub-id pub-id-type="pmid">30320917</pub-id></element-citation></ref><ref id="B31-cancers-11-00846"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Posch</surname><given-names>C.</given-names></name><name><surname>Latorre</surname><given-names>A.</given-names></name><name><surname>Crosby</surname><given-names>M.B.</given-names></name><name><surname>Celli</surname><given-names>A.</given-names></name><name><surname>Latorre</surname><given-names>A.</given-names></name><name><surname>Vujic</surname><given-names>I.</given-names></name><name><surname>Sanlorenzo</surname><given-names>M.</given-names></name><name><surname>Green</surname><given-names>G.A.</given-names></name><name><surname>Weier</surname><given-names>J.</given-names></name><name><surname>Zekhtser</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Detection of GNAQ mutations and reduction of cell viability in uveal melanoma cells with functionalized gold nanoparticles</article-title><source>Biomed. Microdevices</source><year>2015</year><volume>17</volume><fpage>15</fpage><pub-id pub-id-type="doi">10.1007/s10544-014-9908-7</pub-id><pub-id pub-id-type="pmid">25653058</pub-id></element-citation></ref><ref id="B32-cancers-11-00846"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maziarz</surname><given-names>M.</given-names></name><name><surname>Leyme</surname><given-names>A.</given-names></name><name><surname>Marivin</surname><given-names>A.</given-names></name><name><surname>Luebbers</surname><given-names>A.</given-names></name><name><surname>Patel</surname><given-names>P.P.</given-names></name><name><surname>Chen</surname><given-names>Z.</given-names></name><name><surname>Sprang</surname><given-names>S.R.</given-names></name><name><surname>Garcia-Marcos</surname><given-names>M.</given-names></name></person-group><article-title>Atypical activation of the G protein G&#x003b1;q by the oncogenic mutation Q209P</article-title><source>J. Biol. Chem.</source><year>2018</year><volume>293</volume><fpage>19586</fpage><lpage>19599</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA118.005291</pub-id><pub-id pub-id-type="pmid">30352874</pub-id></element-citation></ref><ref id="B33-cancers-11-00846"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zaima</surname><given-names>K.</given-names></name><name><surname>Deguchi</surname><given-names>J.</given-names></name><name><surname>Matsuno</surname><given-names>Y.</given-names></name><name><surname>Kaneda</surname><given-names>T.</given-names></name><name><surname>Hirasawa</surname><given-names>Y.</given-names></name><name><surname>Morita</surname><given-names>H.</given-names></name></person-group><article-title>Vasorelaxant effect of FR900359 from Ardisia crenata on rat aortic artery</article-title><source>J. Nat. Med.</source><year>2013</year><volume>67</volume><fpage>196</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1007/s11418-012-0644-0</pub-id><pub-id pub-id-type="pmid">22388972</pub-id></element-citation></ref><ref id="B34-cancers-11-00846"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schrage</surname><given-names>R.</given-names></name><name><surname>Schmitz</surname><given-names>A.-L.</given-names></name><name><surname>Gaffal</surname><given-names>E.</given-names></name><name><surname>Annala</surname><given-names>S.</given-names></name><name><surname>Kehraus</surname><given-names>S.</given-names></name><name><surname>Wenzel</surname><given-names>D.</given-names></name><name><surname>B&#x000fc;llesbach</surname><given-names>K.M.</given-names></name><name><surname>Bald</surname><given-names>T.</given-names></name><name><surname>Inoue</surname><given-names>A.</given-names></name><name><surname>Shinjo</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>The experimental power of FR900359 to study Gq-regulated biological processes</article-title><source>Nat. Commun.</source><year>2015</year><volume>6</volume><fpage>10156</fpage><pub-id pub-id-type="doi">10.1038/ncomms10156</pub-id><pub-id pub-id-type="pmid">26658454</pub-id></element-citation></ref><ref id="B35-cancers-11-00846"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Makepeace</surname><given-names>C.M.</given-names></name><name><surname>Kaltenbronn</surname><given-names>K.M.</given-names></name><name><surname>Kanai</surname><given-names>S.M.</given-names></name><name><surname>Todd</surname><given-names>T.D.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Broekelmann</surname><given-names>T.J.</given-names></name><name><surname>Rao</surname><given-names>P.K.</given-names></name><name><surname>Cooper</surname><given-names>J.A.</given-names></name><name><surname>Blumer</surname><given-names>K.J.</given-names></name></person-group><article-title>Targeting nucleotide exchange to inhibit constitutively active G protein &#x003b1; subunits in cancer cells</article-title><source>Sci. Signal.</source><year>2018</year><volume>11</volume><fpage>eaao6852</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aao6852</pub-id><pub-id pub-id-type="pmid">30181242</pub-id></element-citation></ref><ref id="B36-cancers-11-00846"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lapadula</surname><given-names>D.</given-names></name><name><surname>Farias</surname><given-names>E.</given-names></name><name><surname>Randolph</surname><given-names>C.E.</given-names></name><name><surname>Purwin</surname><given-names>T.J.</given-names></name><name><surname>McGrath</surname><given-names>D.</given-names></name><name><surname>Charpentier</surname><given-names>T.H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Wu</surname><given-names>S.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Effects of Oncogenic G&#x003b1;q and G&#x003b1;11 Inhibition by FR900359 in Uveal Melanoma</article-title><source>Mol. Cancer Res.</source><year>2019</year><volume>17</volume><fpage>963</fpage><lpage>973</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-18-0574</pub-id><pub-id pub-id-type="pmid">30567972</pub-id></element-citation></ref><ref id="B37-cancers-11-00846"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Annala</surname><given-names>S.</given-names></name><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Shridhar</surname><given-names>N.</given-names></name><name><surname>Eryilmaz</surname><given-names>F.</given-names></name><name><surname>Patt</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Pfeil</surname><given-names>E.M.</given-names></name><name><surname>Cervantes-Villagrana</surname><given-names>R.D.</given-names></name><name><surname>Inoue</surname><given-names>A.</given-names></name><name><surname>H&#x000e4;berlein</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Direct targeting of G&#x003b1;q and G&#x003b1;11 oncoproteins in cancer cells</article-title><source>Sci. Signal.</source><year>2019</year><volume>12</volume><fpage>eaau5948</fpage><pub-id pub-id-type="doi">10.1126/scisignal.aau5948</pub-id><pub-id pub-id-type="pmid">30890659</pub-id></element-citation></ref><ref id="B38-cancers-11-00846"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>X.-F.</given-names></name><name><surname>Zhang</surname><given-names>H.</given-names></name><name><surname>Boesgaard</surname><given-names>M.W.</given-names></name><name><surname>Underwood</surname><given-names>C.R.</given-names></name><name><surname>Br&#x000e4;uner-Osborne</surname><given-names>H.</given-names></name><name><surname>Str&#x000f8;mgaard</surname><given-names>K.</given-names></name></person-group><article-title>Structure-Activity Relationship Studies of the Natural Product Gq/11 Protein Inhibitor YM-254890</article-title><source>ChemMedChem</source><year>2019</year><volume>14</volume><fpage>865</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1002/cmdc.201900018</pub-id><pub-id pub-id-type="pmid">30790465</pub-id></element-citation></ref><ref id="B39-cancers-11-00846"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvajal</surname><given-names>R.D.</given-names></name><name><surname>Sosman</surname><given-names>J.A.</given-names></name><name><surname>Quevedo</surname><given-names>J.F.</given-names></name><name><surname>Milhem</surname><given-names>M.M.</given-names></name><name><surname>Joshua</surname><given-names>A.M.</given-names></name><name><surname>Kudchadkar</surname><given-names>R.R.</given-names></name><name><surname>Linette</surname><given-names>G.P.</given-names></name><name><surname>Gajewski</surname><given-names>T.F.</given-names></name><name><surname>Lutzky</surname><given-names>J.</given-names></name><name><surname>Lawson</surname><given-names>D.H.</given-names></name><etal/></person-group><article-title>Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: A randomized clinical trial</article-title><source>JAMA</source><year>2014</year><volume>311</volume><fpage>2397</fpage><lpage>2405</lpage><pub-id pub-id-type="doi">10.1001/jama.2014.6096</pub-id><pub-id pub-id-type="pmid">24938562</pub-id></element-citation></ref><ref id="B40-cancers-11-00846"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvajal</surname><given-names>R.D.</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S.</given-names></name><name><surname>Kapiteijn</surname><given-names>E.</given-names></name><name><surname>Chapman</surname><given-names>P.B.</given-names></name><name><surname>Frank</surname><given-names>S.</given-names></name><name><surname>Joshua</surname><given-names>A.M.</given-names></name><name><surname>Piulats</surname><given-names>J.M.</given-names></name><name><surname>Wolter</surname><given-names>P.</given-names></name><name><surname>Cocquyt</surname><given-names>V.</given-names></name><name><surname>Chmielowski</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Selumetinib in Combination with Dacarbazine in Patients with Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)</article-title><source>J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>1232</fpage><lpage>1239</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.74.1090</pub-id></element-citation></ref><ref id="B41-cancers-11-00846"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoushtari</surname><given-names>A.N.</given-names></name><name><surname>Kudchadkar</surname><given-names>R.R.</given-names></name><name><surname>Panageas</surname><given-names>K.</given-names></name><name><surname>Murthy</surname><given-names>R.K.</given-names></name><name><surname>Jung</surname><given-names>M.</given-names></name><name><surname>Shah</surname><given-names>R.</given-names></name><name><surname>O&#x02019;Donnell</surname><given-names>B.</given-names></name><name><surname>Khawaja</surname><given-names>T.T.</given-names></name><name><surname>Shames</surname><given-names>Y.</given-names></name><name><surname>Prempeh-Keteku</surname><given-names>N.A.</given-names></name><etal/></person-group><article-title>A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma</article-title><source>J. Clin. Oncol.</source><year>2016</year><volume>34</volume><fpage>9511</fpage><lpage>9511</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.9511</pub-id></element-citation></ref><ref id="B42-cancers-11-00846"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoushtari</surname><given-names>A.N.</given-names></name><name><surname>Ong</surname><given-names>L.T.</given-names></name><name><surname>Schoder</surname><given-names>H.</given-names></name><name><surname>Singh-Kandah</surname><given-names>S.</given-names></name><name><surname>Abbate</surname><given-names>K.T.</given-names></name><name><surname>Postow</surname><given-names>M.A.</given-names></name><name><surname>Callahan</surname><given-names>M.K.</given-names></name><name><surname>Wolchok</surname><given-names>J.</given-names></name><name><surname>Chapman</surname><given-names>P.B.</given-names></name><name><surname>Panageas</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma</article-title><source>Melanoma Res.</source><year>2016</year><volume>26</volume><fpage>272</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000234</pub-id><pub-id pub-id-type="pmid">26795274</pub-id></element-citation></ref><ref id="B43-cancers-11-00846"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhatia</surname><given-names>S.</given-names></name><name><surname>Moon</surname><given-names>J.</given-names></name><name><surname>Margolin</surname><given-names>K.A.</given-names></name><name><surname>Weber</surname><given-names>J.S.</given-names></name><name><surname>Lao</surname><given-names>C.D.</given-names></name><name><surname>Othus</surname><given-names>M.</given-names></name><name><surname>Aparicio</surname><given-names>A.M.</given-names></name><name><surname>Ribas</surname><given-names>A.</given-names></name><name><surname>Sondak</surname><given-names>V.K.</given-names></name></person-group><article-title>Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e48787</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0048787</pub-id><pub-id pub-id-type="pmid">23226204</pub-id></element-citation></ref><ref id="B44-cancers-11-00846"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>J.H.</given-names></name><name><surname>Shi</surname><given-names>D.S.</given-names></name><name><surname>Grossmann</surname><given-names>A.H.</given-names></name><name><surname>Sorensen</surname><given-names>L.K.</given-names></name><name><surname>Tong</surname><given-names>Z.</given-names></name><name><surname>Mleynek</surname><given-names>T.M.</given-names></name><name><surname>Rogers</surname><given-names>A.</given-names></name><name><surname>Zhu</surname><given-names>W.</given-names></name><name><surname>Richards</surname><given-names>J.R.</given-names></name><name><surname>Winter</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>ARF6 Is an Actionable Node that Orchestrates Oncogenic GNAQ Signaling in Uveal Melanoma</article-title><source>Cancer Cell</source><year>2016</year><volume>29</volume><fpage>889</fpage><lpage>904</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2016.04.015</pub-id><pub-id pub-id-type="pmid">27265506</pub-id></element-citation></ref><ref id="B45-cancers-11-00846"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Pratilas</surname><given-names>C.A.</given-names></name><name><surname>Qin</surname><given-names>L.-X.</given-names></name><name><surname>Tadi</surname><given-names>M.</given-names></name><name><surname>Surriga</surname><given-names>O.</given-names></name><name><surname>Carvajal</surname><given-names>R.D.</given-names></name><name><surname>Schwartz</surname><given-names>G.K.</given-names></name></person-group><article-title>Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>3552</fpage><lpage>3561</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3086</pub-id><pub-id pub-id-type="pmid">22550165</pub-id></element-citation></ref><ref id="B46-cancers-11-00846"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Von Euw</surname><given-names>E.</given-names></name><name><surname>Atefi</surname><given-names>M.</given-names></name><name><surname>Attar</surname><given-names>N.</given-names></name><name><surname>Chu</surname><given-names>C.</given-names></name><name><surname>Zachariah</surname><given-names>S.</given-names></name><name><surname>Burgess</surname><given-names>B.L.</given-names></name><name><surname>Mok</surname><given-names>S.</given-names></name><name><surname>Ng</surname><given-names>C.</given-names></name><name><surname>Wong</surname><given-names>D.J.</given-names></name><name><surname>Chmielowski</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines</article-title><source>Mol. Cancer</source><year>2012</year><volume>11</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-11-22</pub-id><pub-id pub-id-type="pmid">22515704</pub-id></element-citation></ref><ref id="B47-cancers-11-00846"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adjei</surname><given-names>A.A.</given-names></name><name><surname>LoRusso</surname><given-names>P.</given-names></name><name><surname>Ribas</surname><given-names>A.</given-names></name><name><surname>Sosman</surname><given-names>J.A.</given-names></name><name><surname>Pavlick</surname><given-names>A.</given-names></name><name><surname>Dy</surname><given-names>G.K.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Gangolli</surname><given-names>E.</given-names></name><name><surname>Kneissl</surname><given-names>M.</given-names></name><name><surname>Faucette</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors</article-title><source>Investig. New Drugs</source><year>2017</year><volume>35</volume><fpage>47</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1007/s10637-016-0391-2</pub-id><pub-id pub-id-type="pmid">27650277</pub-id></element-citation></ref><ref id="B48-cancers-11-00846"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steeb</surname><given-names>T.</given-names></name><name><surname>Wessely</surname><given-names>A.</given-names></name><name><surname>Ruzicka</surname><given-names>T.</given-names></name><name><surname>Heppt</surname><given-names>M.V.</given-names></name><name><surname>Berking</surname><given-names>C.</given-names></name></person-group><article-title>How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma</article-title><source>Eur. J. Cancer</source><year>2018</year><volume>103</volume><fpage>41</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2018.08.005</pub-id><pub-id pub-id-type="pmid">30205280</pub-id></element-citation></ref><ref id="B49-cancers-11-00846"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacKeigan</surname><given-names>J.P.</given-names></name><name><surname>Collins</surname><given-names>T.S.</given-names></name><name><surname>Ting</surname><given-names>J.P.</given-names></name></person-group><article-title>MEK inhibition enhances paclitaxel-induced tumor apoptosis</article-title><source>J. Biol. Chem.</source><year>2000</year><volume>275</volume><fpage>38953</fpage><lpage>38956</lpage><pub-id pub-id-type="doi">10.1074/jbc.C000684200</pub-id><pub-id pub-id-type="pmid">11038347</pub-id></element-citation></ref><ref id="B50-cancers-11-00846"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Decaudin</surname><given-names>D.</given-names></name><name><surname>El Botty</surname><given-names>R.</given-names></name><name><surname>Diallo</surname><given-names>B.</given-names></name><name><surname>Massonnet</surname><given-names>G.</given-names></name><name><surname>Fleury</surname><given-names>J.</given-names></name><name><surname>Naguez</surname><given-names>A.</given-names></name><name><surname>Raymondie</surname><given-names>C.</given-names></name><name><surname>Davies</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Selumetinib-based therapy in uveal melanoma patient-derived xenografts</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>21674</fpage><lpage>21686</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.24670</pub-id><pub-id pub-id-type="pmid">29774094</pub-id></element-citation></ref><ref id="B51-cancers-11-00846"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijkants</surname><given-names>R.</given-names></name><name><surname>Teunisse</surname><given-names>A.</given-names></name><name><surname>de Vries</surname><given-names>J.</given-names></name><name><surname>Ovaa</surname><given-names>H.</given-names></name><name><surname>Jochemsen</surname><given-names>A.</given-names></name></person-group><article-title>Selective PKC&#x003b4; Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms</article-title><source>ACS Chem. Biol.</source><year>2019</year><volume>14</volume><fpage>132</fpage><lpage>136</lpage><pub-id pub-id-type="doi">10.1021/acschembio.8b00292</pub-id><pub-id pub-id-type="pmid">30525429</pub-id></element-citation></ref><ref id="B52-cancers-11-00846"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>M.</given-names></name><name><surname>Fletcher</surname><given-names>J.A.</given-names></name><name><surname>Hodi</surname><given-names>F.S.</given-names></name></person-group><article-title>Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-&#x003ba;B pathways</article-title><source>Mol. Cancer Ther.</source><year>2012</year><volume>11</volume><fpage>1905</fpage><lpage>1914</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-12-0121</pub-id><pub-id pub-id-type="pmid">22653968</pub-id></element-citation></ref><ref id="B53-cancers-11-00846"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piperno-Neumann</surname><given-names>S.</given-names></name><name><surname>Kapiteijn</surname><given-names>E.</given-names></name><name><surname>Larkin</surname><given-names>J.M.G.</given-names></name><name><surname>Carvajal</surname><given-names>R.D.</given-names></name><name><surname>Luke</surname><given-names>J.J.</given-names></name><name><surname>Seifert</surname><given-names>H.</given-names></name><name><surname>Roozen</surname><given-names>I.</given-names></name><name><surname>Zoubir</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Choudhury</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Phase I dose-escalation study of the protein kinase C (PKC) inhibitor AEB071 in patients with metastatic uveal melanoma</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>9030</fpage><lpage>9030</lpage><pub-id pub-id-type="doi">10.1200/jco.2014.32.15_suppl.9030</pub-id></element-citation></ref><ref id="B54-cancers-11-00846"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wu</surname><given-names>Q.</given-names></name><name><surname>Tan</surname><given-names>L.</given-names></name><name><surname>Porter</surname><given-names>D.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name><name><surname>Emery</surname><given-names>C.</given-names></name><name><surname>Bastian</surname><given-names>B.C.</given-names></name></person-group><article-title>Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>4724</fpage><lpage>4734</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.418</pub-id><pub-id pub-id-type="pmid">24141786</pub-id></element-citation></ref><ref id="B55-cancers-11-00846"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalili</surname><given-names>J.S.</given-names></name><name><surname>Yu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hayes</surname><given-names>B.C.</given-names></name><name><surname>Davies</surname><given-names>M.A.</given-names></name><name><surname>Lizee</surname><given-names>G.</given-names></name><name><surname>Esmaeli</surname><given-names>B.</given-names></name><name><surname>Woodman</surname><given-names>S.E.</given-names></name></person-group><article-title>Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>4345</fpage><lpage>4355</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-3227</pub-id><pub-id pub-id-type="pmid">22733540</pub-id></element-citation></ref><ref id="B56-cancers-11-00846"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Musi</surname><given-names>E.</given-names></name><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>de Stanchina</surname><given-names>E.</given-names></name><name><surname>Schwartz</surname><given-names>G.K.</given-names></name></person-group><article-title>The phosphoinositide 3-kinase &#x003b1; selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells</article-title><source>Mol. Cancer Ther.</source><year>2014</year><volume>13</volume><fpage>1044</fpage><lpage>1053</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0550</pub-id><pub-id pub-id-type="pmid">24563540</pub-id></element-citation></ref><ref id="B57-cancers-11-00846"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amirouchene-Angelozzi</surname><given-names>N.</given-names></name><name><surname>Frisch-Dit-Leitz</surname><given-names>E.</given-names></name><name><surname>Carita</surname><given-names>G.</given-names></name><name><surname>Dahmani</surname><given-names>A.</given-names></name><name><surname>Raymondie</surname><given-names>C.</given-names></name><name><surname>Liot</surname><given-names>G.</given-names></name><name><surname>Gentien</surname><given-names>D.</given-names></name><name><surname>N&#x000e9;mati</surname><given-names>F.</given-names></name><name><surname>Decaudin</surname><given-names>D.</given-names></name><name><surname>Roman-Roman</surname><given-names>S.</given-names></name><etal/></person-group><article-title>The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>23633</fpage><lpage>23646</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.8054</pub-id><pub-id pub-id-type="pmid">26988753</pub-id></element-citation></ref><ref id="B58-cancers-11-00846"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carita</surname><given-names>G.</given-names></name><name><surname>Frisch-Dit-Leitz</surname><given-names>E.</given-names></name><name><surname>Dahmani</surname><given-names>A.</given-names></name><name><surname>Raymondie</surname><given-names>C.</given-names></name><name><surname>Cassoux</surname><given-names>N.</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S.</given-names></name><name><surname>N&#x000e9;mati</surname><given-names>F.</given-names></name><name><surname>Laurent</surname><given-names>C.</given-names></name><name><surname>De Koning</surname><given-names>L.</given-names></name><name><surname>Halilovic</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>33542</fpage><lpage>33556</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9552</pub-id><pub-id pub-id-type="pmid">27507190</pub-id></element-citation></ref><ref id="B59-cancers-11-00846"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>R.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name></person-group><article-title>The Hippo Pathway: Biology and Pathophysiology</article-title><source>Annu. Rev. Biochem.</source><year>2018</year><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111829</pub-id><pub-id pub-id-type="pmid">30566373</pub-id></element-citation></ref><ref id="B60-cancers-11-00846"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harvey</surname><given-names>K.F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Thomas</surname><given-names>D.M.</given-names></name></person-group><article-title>The Hippo pathway and human cancer</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="doi">10.1038/nrc3458</pub-id><pub-id pub-id-type="pmid">23467301</pub-id></element-citation></ref><ref id="B61-cancers-11-00846"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.-X.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name></person-group><article-title>The Hippo pathway: Regulators and regulations</article-title><source>Genes Dev.</source><year>2013</year><volume>27</volume><fpage>355</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1101/gad.210773.112</pub-id><pub-id pub-id-type="pmid">23431053</pub-id></element-citation></ref><ref id="B62-cancers-11-00846"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taha</surname><given-names>Z.</given-names></name><name><surname>Janse van Rensburg</surname><given-names>H.J.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name></person-group><article-title>The Hippo Pathway: Immunity and Cancer</article-title><source>Cancers</source><year>2018</year><volume>10</volume><elocation-id>94</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10040094</pub-id><pub-id pub-id-type="pmid">29597279</pub-id></element-citation></ref><ref id="B63-cancers-11-00846"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warren</surname><given-names>J.S.A.</given-names></name><name><surname>Xiao</surname><given-names>Y.</given-names></name><name><surname>Lamar</surname><given-names>J.M.</given-names></name></person-group><article-title>YAP/TAZ Activation as a Target for Treating Metastatic Cancer</article-title><source>Cancers</source><year>2018</year><volume>10</volume><elocation-id>115</elocation-id><pub-id pub-id-type="doi">10.3390/cancers10040115</pub-id><pub-id pub-id-type="pmid">29642615</pub-id></element-citation></ref><ref id="B64-cancers-11-00846"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F.-X.</given-names></name><name><surname>Luo</surname><given-names>J.</given-names></name><name><surname>Mo</surname><given-names>J.-S.</given-names></name><name><surname>Liu</surname><given-names>G.</given-names></name><name><surname>Kim</surname><given-names>Y.C.</given-names></name><name><surname>Meng</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>L.</given-names></name><name><surname>Peyman</surname><given-names>G.</given-names></name><name><surname>Ouyang</surname><given-names>H.</given-names></name><name><surname>Jiang</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>822</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.04.017</pub-id><pub-id pub-id-type="pmid">24882516</pub-id></element-citation></ref><ref id="B65-cancers-11-00846"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Degese</surname><given-names>M.S.</given-names></name><name><surname>Iglesias-Bartolome</surname><given-names>R.</given-names></name><name><surname>Vaque</surname><given-names>J.P.</given-names></name><name><surname>Molinolo</surname><given-names>A.A.</given-names></name><name><surname>Rodrigues</surname><given-names>M.</given-names></name><name><surname>Zaidi</surname><given-names>M.R.</given-names></name><name><surname>Ksander</surname><given-names>B.R.</given-names></name><name><surname>Merlino</surname><given-names>G.</given-names></name><name><surname>Sodhi</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>831</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.04.016</pub-id><pub-id pub-id-type="pmid">24882515</pub-id></element-citation></ref><ref id="B66-cancers-11-00846"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B.</given-names></name><name><surname>Ye</surname><given-names>X.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>L.</given-names></name><name><surname>Li</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>J.D.</given-names></name><name><surname>Wang</surname><given-names>C.-Y.</given-names></name><name><surname>Chinnaiyan</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>TEAD mediates YAP-dependent gene induction and growth control</article-title><source>Genes Dev.</source><year>2008</year><volume>22</volume><fpage>1962</fpage><lpage>1971</lpage><pub-id pub-id-type="doi">10.1101/gad.1664408</pub-id><pub-id pub-id-type="pmid">18579750</pub-id></element-citation></ref><ref id="B67-cancers-11-00846"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyubasyuk</surname><given-names>V.</given-names></name><name><surname>Ouyang</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>F.-X.</given-names></name><name><surname>Guan</surname><given-names>K.-L.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name></person-group><article-title>YAP inhibition blocks uveal melanogenesis driven by GNAQ or GNA11 mutations</article-title><source>Mol. Cell. Oncol.</source><year>2015</year><volume>2</volume><fpage>e970957</fpage><pub-id pub-id-type="doi">10.4161/23723548.2014.970957</pub-id><pub-id pub-id-type="pmid">27308390</pub-id></element-citation></ref><ref id="B68-cancers-11-00846"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Gutkind</surname><given-names>J.S.</given-names></name></person-group><article-title>Oncotargeting G proteins: The Hippo in the room</article-title><source>Oncotarget</source><year>2014</year><volume>5</volume><fpage>10997</fpage><lpage>10999</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.2815</pub-id><pub-id pub-id-type="pmid">25526026</pub-id></element-citation></ref><ref id="B69-cancers-11-00846"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>M.G.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>GNAQ/11 mutations in uveal melanoma: Is YAP the key to targeted therapy?</article-title><source>Cancer Cell</source><year>2014</year><volume>25</volume><fpage>714</fpage><lpage>715</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2014.05.028</pub-id><pub-id pub-id-type="pmid">24937456</pub-id></element-citation></ref><ref id="B70-cancers-11-00846"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>X.</given-names></name><name><surname>Arang</surname><given-names>N.</given-names></name><name><surname>Rigiracciolo</surname><given-names>D.C.</given-names></name><name><surname>Lee</surname><given-names>J.S.</given-names></name><name><surname>Yeerna</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Lubrano</surname><given-names>S.</given-names></name><name><surname>Kishore</surname><given-names>A.</given-names></name><name><surname>Pachter</surname><given-names>J.A.</given-names></name><name><surname>K&#x000f6;nig</surname><given-names>G.M.</given-names></name><etal/></person-group><article-title>A Platform of Synthetic Lethal Gene Interaction Networks Reveals that the GNAQ Uveal Melanoma Oncogene Controls the Hippo Pathway through FAK</article-title><source>Cancer Cell</source><year>2019</year><volume>35</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2019.01.009</pub-id><pub-id pub-id-type="pmid">30773340</pub-id></element-citation></ref><ref id="B71-cancers-11-00846"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradner</surname><given-names>J.E.</given-names></name><name><surname>Hnisz</surname><given-names>D.</given-names></name><name><surname>Young</surname><given-names>R.A.</given-names></name></person-group><article-title>Transcriptional Addiction in Cancer</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>629</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.12.013</pub-id><pub-id pub-id-type="pmid">28187285</pub-id></element-citation></ref><ref id="B72-cancers-11-00846"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A.</given-names></name><name><surname>Stei</surname><given-names>M.M.</given-names></name><name><surname>Fr&#x000f6;hlich</surname><given-names>H.</given-names></name><name><surname>Holz</surname><given-names>F.G.</given-names></name><name><surname>Loeffler</surname><given-names>K.U.</given-names></name><name><surname>Herwig-Carl</surname><given-names>M.C.</given-names></name></person-group><article-title>Genetic and epigenetic insights into uveal melanoma</article-title><source>Clin. Genet.</source><year>2018</year><volume>93</volume><fpage>952</fpage><lpage>961</lpage><pub-id pub-id-type="doi">10.1111/cge.13136</pub-id><pub-id pub-id-type="pmid">28902406</pub-id></element-citation></ref><ref id="B73-cancers-11-00846"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herlihy</surname><given-names>N.</given-names></name><name><surname>Dogrus&#x000f6;z</surname><given-names>M.</given-names></name><name><surname>van Essen</surname><given-names>T.H.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name><name><surname>van der Velden</surname><given-names>P.A.</given-names></name><name><surname>van Eggermond</surname><given-names>M.C.J.A.</given-names></name><name><surname>Haasnoot</surname><given-names>G.W.</given-names></name><name><surname>van den Elsen</surname><given-names>P.J.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Skewed expression of the genes encoding epigenetic modifiers in high-risk uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2015</year><volume>56</volume><fpage>1447</fpage><lpage>1458</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-15250</pub-id><pub-id pub-id-type="pmid">25593028</pub-id></element-citation></ref><ref id="B74-cancers-11-00846"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Falkenberg</surname><given-names>K.J.</given-names></name><name><surname>Johnstone</surname><given-names>R.W.</given-names></name></person-group><article-title>Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders</article-title><source>Nat. Rev. Drug Discov.</source><year>2014</year><volume>13</volume><fpage>673</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1038/nrd4360</pub-id><pub-id pub-id-type="pmid">25131830</pub-id></element-citation></ref><ref id="B75-cancers-11-00846"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landreville</surname><given-names>S.</given-names></name><name><surname>Agapova</surname><given-names>O.A.</given-names></name><name><surname>Matatall</surname><given-names>K.A.</given-names></name><name><surname>Kneass</surname><given-names>Z.T.</given-names></name><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Lee</surname><given-names>R.S.</given-names></name><name><surname>Bowcock</surname><given-names>A.M.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2012</year><volume>18</volume><fpage>408</fpage><lpage>416</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-0946</pub-id><pub-id pub-id-type="pmid">22038994</pub-id></element-citation></ref><ref id="B76-cancers-11-00846"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>D.-N.</given-names></name><name><surname>Dong</surname><given-names>X.D.</given-names></name><name><surname>Yan</surname><given-names>D.</given-names></name><name><surname>Tu</surname><given-names>L.</given-names></name></person-group><article-title>Epigenetics, microRNAs, and carcinogenesis: Functional role of microRNA-137 in uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2011</year><volume>52</volume><fpage>1193</fpage><lpage>1199</lpage><pub-id pub-id-type="doi">10.1167/iovs.10-5272</pub-id><pub-id pub-id-type="pmid">21051724</pub-id></element-citation></ref><ref id="B77-cancers-11-00846"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>W.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Jin</surname><given-names>B.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name></person-group><article-title>Class III-specific HDAC inhibitor Tenovin-6 induces apoptosis, suppresses migration and eliminates cancer stem cells in uveal melanoma</article-title><source>Sci. Rep.</source><year>2016</year><volume>6</volume><fpage>22622</fpage><pub-id pub-id-type="doi">10.1038/srep22622</pub-id><pub-id pub-id-type="pmid">26940009</pub-id></element-citation></ref><ref id="B78-cancers-11-00846"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klisovic</surname><given-names>D.D.</given-names></name><name><surname>Klisovic</surname><given-names>M.I.</given-names></name><name><surname>Effron</surname><given-names>D.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Marcucci</surname><given-names>G.</given-names></name><name><surname>Katz</surname><given-names>S.E.</given-names></name></person-group><article-title>Depsipeptide inhibits migration of primary and metastatic uveal melanoma cell lines in vitro: A potential strategy for uveal melanoma</article-title><source>Melanoma Res.</source><year>2005</year><volume>15</volume><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1097/00008390-200506000-00002</pub-id><pub-id pub-id-type="pmid">15917695</pub-id></element-citation></ref><ref id="B79-cancers-11-00846"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venza</surname><given-names>I.</given-names></name><name><surname>Visalli</surname><given-names>M.</given-names></name><name><surname>Oteri</surname><given-names>R.</given-names></name><name><surname>Teti</surname><given-names>D.</given-names></name><name><surname>Venza</surname><given-names>M.</given-names></name></person-group><article-title>Class I-specific histone deacetylase inhibitor MS-275 overrides TRAIL-resistance in melanoma cells by downregulating c-FLIP</article-title><source>Int. Immunopharmacol.</source><year>2014</year><volume>21</volume><fpage>439</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2014.05.024</pub-id><pub-id pub-id-type="pmid">24946096</pub-id></element-citation></ref><ref id="B80-cancers-11-00846"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heijkants</surname><given-names>R.</given-names></name><name><surname>Willekens</surname><given-names>K.</given-names></name><name><surname>Schoonderwoerd</surname><given-names>M.</given-names></name><name><surname>Teunisse</surname><given-names>A.</given-names></name><name><surname>Nieveen</surname><given-names>M.</given-names></name><name><surname>Radaelli</surname><given-names>E.</given-names></name><name><surname>Hawinkels</surname><given-names>L.</given-names></name><name><surname>Marine</surname><given-names>J.-C.</given-names></name><name><surname>Jochemsen</surname><given-names>A.</given-names></name></person-group><article-title>Combined inhibition of CDK and HDAC as a promising therapeutic strategy for both cutaneous and uveal metastatic melanoma</article-title><source>Oncotarget</source><year>2018</year><volume>9</volume><fpage>6174</fpage><lpage>6187</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.23485</pub-id><pub-id pub-id-type="pmid">29464063</pub-id></element-citation></ref><ref id="B81-cancers-11-00846"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Liu</surname><given-names>M.</given-names></name><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name></person-group><article-title>In vitro and in vivo anti-uveal melanoma activity of JSL-1, a novel HDAC inhibitor</article-title><source>Cancer Lett.</source><year>2017</year><volume>400</volume><fpage>47</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2017.04.028</pub-id><pub-id pub-id-type="pmid">28455241</pub-id></element-citation></ref><ref id="B82-cancers-11-00846"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venza</surname><given-names>I.</given-names></name><name><surname>Visalli</surname><given-names>M.</given-names></name><name><surname>Oteri</surname><given-names>R.</given-names></name><name><surname>Cucinotta</surname><given-names>M.</given-names></name><name><surname>Teti</surname><given-names>D.</given-names></name><name><surname>Venza</surname><given-names>M.</given-names></name></person-group><article-title>Class II-specific histone deacetylase inhibitors MC1568 and MC1575 suppress IL-8 expression in human melanoma cells</article-title><source>Pigment. Cell Melanoma Res.</source><year>2013</year><volume>26</volume><fpage>193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12049</pub-id><pub-id pub-id-type="pmid">23176534</pub-id></element-citation></ref><ref id="B83-cancers-11-00846"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moschos</surname><given-names>M.M.</given-names></name><name><surname>Dettoraki</surname><given-names>M.</given-names></name><name><surname>Androudi</surname><given-names>S.</given-names></name><name><surname>Kalogeropoulos</surname><given-names>D.</given-names></name><name><surname>Lavaris</surname><given-names>A.</given-names></name><name><surname>Garmpis</surname><given-names>N.</given-names></name><name><surname>Damaskos</surname><given-names>C.</given-names></name><name><surname>Garmpi</surname><given-names>A.</given-names></name><name><surname>Tsatsos</surname><given-names>M.</given-names></name></person-group><article-title>The Role of Histone Deacetylase Inhibitors in Uveal Melanoma: Current Evidence</article-title><source>Anticancer Res.</source><year>2018</year><volume>38</volume><fpage>3817</fpage><lpage>3824</lpage><pub-id pub-id-type="doi">10.21873/anticanres.12665</pub-id><pub-id pub-id-type="pmid">29970501</pub-id></element-citation></ref><ref id="B84-cancers-11-00846"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>L.</given-names></name><name><surname>Roberts</surname><given-names>J.L.</given-names></name><name><surname>Sander</surname><given-names>C.</given-names></name><name><surname>Lalani</surname><given-names>A.S.</given-names></name><name><surname>Kirkwood</surname><given-names>J.M.</given-names></name><name><surname>Hancock</surname><given-names>J.F.</given-names></name><name><surname>Poklepovic</surname><given-names>A.</given-names></name><name><surname>Dent</surname><given-names>P.</given-names></name></person-group><article-title>Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, G&#x003b1;q and G&#x003b1;11 and kill uveal melanoma cells</article-title><source>Cancer Biol. Ther.</source><year>2019</year><volume>20</volume><fpage>700</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.1080/15384047.2018.1551747</pub-id><pub-id pub-id-type="pmid">30571927</pub-id></element-citation></ref><ref id="B85-cancers-11-00846"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amaro</surname><given-names>A.</given-names></name><name><surname>Mirisola</surname><given-names>V.</given-names></name><name><surname>Angelini</surname><given-names>G.</given-names></name><name><surname>Musso</surname><given-names>A.</given-names></name><name><surname>Tosetti</surname><given-names>F.</given-names></name><name><surname>Esposito</surname><given-names>A.I.</given-names></name><name><surname>Perri</surname><given-names>P.</given-names></name><name><surname>Lanza</surname><given-names>F.</given-names></name><name><surname>Nasciuti</surname><given-names>F.</given-names></name><name><surname>Mosci</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Evidence of epidermal growth factor receptor expression in uveal melanoma: Inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity</article-title><source>Eur. J. Cancer</source><year>2013</year><volume>49</volume><fpage>3353</fpage><lpage>3365</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.06.011</pub-id><pub-id pub-id-type="pmid">23849826</pub-id></element-citation></ref><ref id="B86-cancers-11-00846"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orillion</surname><given-names>A.</given-names></name><name><surname>Hashimoto</surname><given-names>A.</given-names></name><name><surname>Damayanti</surname><given-names>N.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Adelaiye-Ogala</surname><given-names>R.</given-names></name><name><surname>Arisa</surname><given-names>S.</given-names></name><name><surname>Chintala</surname><given-names>S.</given-names></name><name><surname>Ordentlich</surname><given-names>P.</given-names></name><name><surname>Kao</surname><given-names>C.</given-names></name><name><surname>Elzey</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2017</year><volume>23</volume><fpage>5187</fpage><lpage>5201</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-0741</pub-id><pub-id pub-id-type="pmid">28698201</pub-id></element-citation></ref><ref id="B87-cancers-11-00846"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>P.A.</given-names></name><name><surname>Baylin</surname><given-names>S.B.</given-names></name></person-group><article-title>The epigenomics of cancer</article-title><source>Cell</source><year>2007</year><volume>128</volume><fpage>683</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.01.029</pub-id><pub-id pub-id-type="pmid">17320506</pub-id></element-citation></ref><ref id="B88-cancers-11-00846"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Velden</surname><given-names>P.A.</given-names></name><name><surname>Metzelaar-Blok</surname><given-names>J.A.</given-names></name><name><surname>Bergman</surname><given-names>W.</given-names></name><name><surname>Monique</surname><given-names>H.</given-names></name><name><surname>Hurks</surname><given-names>H.</given-names></name><name><surname>Frants</surname><given-names>R.R.</given-names></name><name><surname>Gruis</surname><given-names>N.A.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Promoter hypermethylation: A common cause of reduced p16(INK4a) expression in uveal melanoma</article-title><source>Cancer Res.</source><year>2001</year><volume>61</volume><fpage>5303</fpage><lpage>5306</lpage><pub-id pub-id-type="pmid">11431374</pub-id></element-citation></ref><ref id="B89-cancers-11-00846"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venza</surname><given-names>M.</given-names></name><name><surname>Visalli</surname><given-names>M.</given-names></name><name><surname>Biondo</surname><given-names>C.</given-names></name><name><surname>Lentini</surname><given-names>M.</given-names></name><name><surname>Catalano</surname><given-names>T.</given-names></name><name><surname>Teti</surname><given-names>D.</given-names></name><name><surname>Venza</surname><given-names>I.</given-names></name></person-group><article-title>Epigenetic regulation of p14ARF and p16INK4A expression in cutaneous and uveal melanoma</article-title><source>Biochim. Biophys. Acta</source><year>2015</year><volume>1849</volume><fpage>247</fpage><lpage>256</lpage><pub-id pub-id-type="doi">10.1016/j.bbagrm.2014.12.004</pub-id><pub-id pub-id-type="pmid">25497382</pub-id></element-citation></ref><ref id="B90-cancers-11-00846"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Velden</surname><given-names>P.A.</given-names></name><name><surname>Zuidervaart</surname><given-names>W.</given-names></name><name><surname>Hurks</surname><given-names>M.H.M.H.</given-names></name><name><surname>Pavey</surname><given-names>S.</given-names></name><name><surname>Ksander</surname><given-names>B.R.</given-names></name><name><surname>Krijgsman</surname><given-names>E.</given-names></name><name><surname>Frants</surname><given-names>R.R.</given-names></name><name><surname>Tensen</surname><given-names>C.P.</given-names></name><name><surname>Willemze</surname><given-names>R.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Expression profiling reveals that methylation of TIMP3 is involved in uveal melanoma development</article-title><source>Int. J. Cancer</source><year>2003</year><volume>106</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1002/ijc.11262</pub-id><pub-id pub-id-type="pmid">12845640</pub-id></element-citation></ref><ref id="B91-cancers-11-00846"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gollob</surname><given-names>J.A.</given-names></name><name><surname>Sciambi</surname><given-names>C.J.</given-names></name></person-group><article-title>Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2007</year><volume>13</volume><fpage>5219</fpage><lpage>5225</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-0816</pub-id><pub-id pub-id-type="pmid">17785578</pub-id></element-citation></ref><ref id="B92-cancers-11-00846"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajaii</surname><given-names>F.</given-names></name><name><surname>Asnaghi</surname><given-names>L.</given-names></name><name><surname>Enke</surname><given-names>R.</given-names></name><name><surname>Merbs</surname><given-names>S.L.</given-names></name><name><surname>Handa</surname><given-names>J.T.</given-names></name><name><surname>Eberhart</surname><given-names>C.G.</given-names></name></person-group><article-title>The demethylating agent 5-Aza reduces the growth, invasiveness, and clonogenicity of uveal and cutaneous melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2014</year><volume>55</volume><fpage>6178</fpage><lpage>6186</lpage><pub-id pub-id-type="doi">10.1167/iovs.14-13933</pub-id><pub-id pub-id-type="pmid">25146981</pub-id></element-citation></ref><ref id="B93-cancers-11-00846"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Field</surname><given-names>M.G.</given-names></name><name><surname>Durante</surname><given-names>M.A.</given-names></name><name><surname>Anbunathan</surname><given-names>H.</given-names></name><name><surname>Cai</surname><given-names>L.Z.</given-names></name><name><surname>Decatur</surname><given-names>C.L.</given-names></name><name><surname>Bowcock</surname><given-names>A.M.</given-names></name><name><surname>Kurtenbach</surname><given-names>S.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>Punctuated evolution of canonical genomic aberrations in uveal melanoma</article-title><source>Nat. Commun.</source><year>2018</year><volume>9</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.1038/s41467-017-02428-w</pub-id><pub-id pub-id-type="pmid">29317634</pub-id></element-citation></ref><ref id="B94-cancers-11-00846"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yen</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>X.</given-names></name><name><surname>Cooper</surname><given-names>J.A.</given-names></name><name><surname>Mitra</surname><given-names>R.D.</given-names></name><name><surname>Onken</surname><given-names>M.D.</given-names></name></person-group><article-title>Transposase mapping identifies the genomic targets of BAP1 in uveal melanoma</article-title><source>BMC Med. Genomics</source><year>2018</year><volume>11</volume><elocation-id>97</elocation-id><pub-id pub-id-type="doi">10.1186/s12920-018-0424-0</pub-id><pub-id pub-id-type="pmid">30400891</pub-id></element-citation></ref><ref id="B95-cancers-11-00846"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stathis</surname><given-names>A.</given-names></name><name><surname>Bertoni</surname><given-names>F.</given-names></name></person-group><article-title>BET Proteins as Targets for Anticancer Treatment</article-title><source>Cancer Discov.</source><year>2018</year><volume>8</volume><fpage>24</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0605</pub-id><pub-id pub-id-type="pmid">29263030</pub-id></element-citation></ref><ref id="B96-cancers-11-00846"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manzotti</surname><given-names>G.</given-names></name><name><surname>Ciarrocchi</surname><given-names>A.</given-names></name><name><surname>Sancisi</surname><given-names>V.</given-names></name></person-group><article-title>Inhibition of BET Proteins and Histone Deacetylase (HDACs): Crossing Roads in Cancer Therapy</article-title><source>Cancers</source><year>2019</year><volume>11</volume><elocation-id>304</elocation-id><pub-id pub-id-type="doi">10.3390/cancers11030304</pub-id><pub-id pub-id-type="pmid">30841549</pub-id></element-citation></ref><ref id="B97-cancers-11-00846"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delmore</surname><given-names>J.E.</given-names></name><name><surname>Issa</surname><given-names>G.C.</given-names></name><name><surname>Lemieux</surname><given-names>M.E.</given-names></name><name><surname>Rahl</surname><given-names>P.B.</given-names></name><name><surname>Shi</surname><given-names>J.</given-names></name><name><surname>Jacobs</surname><given-names>H.M.</given-names></name><name><surname>Kastritis</surname><given-names>E.</given-names></name><name><surname>Gilpatrick</surname><given-names>T.</given-names></name><name><surname>Paranal</surname><given-names>R.M.</given-names></name><name><surname>Qi</surname><given-names>J.</given-names></name><etal/></person-group><article-title>BET bromodomain inhibition as a therapeutic strategy to target c-Myc</article-title><source>Cell</source><year>2011</year><volume>146</volume><fpage>904</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.08.017</pub-id><pub-id pub-id-type="pmid">21889194</pub-id></element-citation></ref><ref id="B98-cancers-11-00846"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Sawle</surname><given-names>A.D.</given-names></name><name><surname>Musi</surname><given-names>E.</given-names></name><name><surname>Schwartz</surname><given-names>G.K.</given-names></name></person-group><article-title>BRD4-targeted therapy induces Myc-independent cytotoxicity in Gnaq/11-mutatant uveal melanoma cells</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>33397</fpage><lpage>33409</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.5179</pub-id><pub-id pub-id-type="pmid">26397223</pub-id></element-citation></ref><ref id="B99-cancers-11-00846"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozer</surname><given-names>H.G.</given-names></name><name><surname>El-Gamal</surname><given-names>D.</given-names></name><name><surname>Powell</surname><given-names>B.</given-names></name><name><surname>Hing</surname><given-names>Z.A.</given-names></name><name><surname>Blachly</surname><given-names>J.S.</given-names></name><name><surname>Harrington</surname><given-names>B.</given-names></name><name><surname>Mitchell</surname><given-names>S.</given-names></name><name><surname>Grieselhuber</surname><given-names>N.R.</given-names></name><name><surname>Williams</surname><given-names>K.</given-names></name><name><surname>Lai</surname><given-names>T.-H.</given-names></name><etal/></person-group><article-title>BRD4 Profiling Identifies Critical Chronic Lymphocytic Leukemia Oncogenic Circuits and Reveals Sensitivity to PLX51107, a Novel Structurally Distinct BET Inhibitor</article-title><source>Cancer Discov.</source><year>2018</year><volume>8</volume><fpage>458</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-0902</pub-id><pub-id pub-id-type="pmid">29386193</pub-id></element-citation></ref><ref id="B100-cancers-11-00846"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chua</surname><given-names>V.</given-names></name><name><surname>Orloff</surname><given-names>M.</given-names></name><name><surname>Teh</surname><given-names>J.L.</given-names></name><name><surname>Sugase</surname><given-names>T.</given-names></name><name><surname>Liao</surname><given-names>C.</given-names></name><name><surname>Purwin</surname><given-names>T.J.</given-names></name><name><surname>Lam</surname><given-names>B.Q.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Carvajal</surname><given-names>R.D.</given-names></name><etal/></person-group><article-title>Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma</article-title><source>EMBO Mol. Med.</source><year>2019</year><volume>11</volume><fpage>e9081</fpage><pub-id pub-id-type="doi">10.15252/emmm.201809081</pub-id><pub-id pub-id-type="pmid">30610113</pub-id></element-citation></ref><ref id="B101-cancers-11-00846"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>F.P.</given-names></name><name><surname>Clarke</surname><given-names>K.</given-names></name><name><surname>Kalirai</surname><given-names>H.</given-names></name><name><surname>Kenyani</surname><given-names>J.</given-names></name><name><surname>Shahidipour</surname><given-names>H.</given-names></name><name><surname>Falciani</surname><given-names>F.</given-names></name><name><surname>Coulson</surname><given-names>J.M.</given-names></name><name><surname>Sacco</surname><given-names>J.J.</given-names></name><name><surname>Coupland</surname><given-names>S.E.</given-names></name><name><surname>Eyers</surname><given-names>P.A.</given-names></name></person-group><article-title>Kinome-wide transcriptional profiling of uveal melanoma reveals new vulnerabilities to targeted therapeutics</article-title><source>Pigment Cell Melanoma Res.</source><year>2018</year><volume>31</volume><fpage>253</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12650</pub-id><pub-id pub-id-type="pmid">28972303</pub-id></element-citation></ref><ref id="B102-cancers-11-00846"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangemi</surname><given-names>R.</given-names></name><name><surname>Mirisola</surname><given-names>V.</given-names></name><name><surname>Barisione</surname><given-names>G.</given-names></name><name><surname>Fabbi</surname><given-names>M.</given-names></name><name><surname>Brizzolara</surname><given-names>A.</given-names></name><name><surname>Lanza</surname><given-names>F.</given-names></name><name><surname>Mosci</surname><given-names>C.</given-names></name><name><surname>Salvi</surname><given-names>S.</given-names></name><name><surname>Gualco</surname><given-names>M.</given-names></name><name><surname>Truini</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e29989</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0029989</pub-id><pub-id pub-id-type="pmid">22267972</pub-id></element-citation></ref><ref id="B103-cancers-11-00846"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boukerche</surname><given-names>H.</given-names></name><name><surname>Su</surname><given-names>Z.-Z.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Baril</surname><given-names>P.</given-names></name><name><surname>Balme</surname><given-names>B.</given-names></name><name><surname>Thomas</surname><given-names>L.</given-names></name><name><surname>Randolph</surname><given-names>A.</given-names></name><name><surname>Valerie</surname><given-names>K.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Fisher</surname><given-names>P.B.</given-names></name></person-group><article-title>mda-9/Syntenin: A positive regulator of melanoma metastasis</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>10901</fpage><lpage>10911</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1614</pub-id><pub-id pub-id-type="pmid">16322237</pub-id></element-citation></ref><ref id="B104-cancers-11-00846"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kegelman</surname><given-names>T.P.</given-names></name><name><surname>Das</surname><given-names>S.K.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Menezes</surname><given-names>M.E.</given-names></name><name><surname>Bhoopathi</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>X.-Y.</given-names></name><name><surname>Pellecchia</surname><given-names>M.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Fisher</surname><given-names>P.B.</given-names></name></person-group><article-title>Targeting tumor invasion: The roles of MDA-9/Syntenin</article-title><source>Expert Opin. Ther. Targets</source><year>2015</year><volume>19</volume><fpage>97</fpage><lpage>112</lpage><pub-id pub-id-type="doi">10.1517/14728222.2014.959495</pub-id><pub-id pub-id-type="pmid">25219541</pub-id></element-citation></ref><ref id="B105-cancers-11-00846"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Wan</surname><given-names>X.</given-names></name></person-group><article-title>A PDZ Protein MDA-9/Syntenin: As a Target for Cancer Therapy</article-title><source>Comput. Struct. Biotechnol. J.</source><year>2019</year><volume>17</volume><fpage>136</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.csbj.2019.01.002</pub-id><pub-id pub-id-type="pmid">30766662</pub-id></element-citation></ref><ref id="B106-cancers-11-00846"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Qu</surname><given-names>J.</given-names></name><name><surname>Zhou</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>Y.</given-names></name><name><surname>Jia</surname><given-names>L.</given-names></name><name><surname>Huang</surname><given-names>X.</given-names></name><name><surname>Qian</surname><given-names>Z.</given-names></name><name><surname>Xia</surname><given-names>J.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name></person-group><article-title>Syntenin-targeted peptide blocker inhibits progression of cancer cells</article-title><source>Eur. J. Med. Chem.</source><year>2018</year><volume>154</volume><fpage>354</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1016/j.ejmech.2018.05.015</pub-id><pub-id pub-id-type="pmid">29857221</pub-id></element-citation></ref><ref id="B107-cancers-11-00846"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kegelman</surname><given-names>T.P.</given-names></name><name><surname>Wu</surname><given-names>B.</given-names></name><name><surname>Das</surname><given-names>S.K.</given-names></name><name><surname>Talukdar</surname><given-names>S.</given-names></name><name><surname>Beckta</surname><given-names>J.M.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Emdad</surname><given-names>L.</given-names></name><name><surname>Valerie</surname><given-names>K.</given-names></name><name><surname>Sarkar</surname><given-names>D.</given-names></name><name><surname>Furnari</surname><given-names>F.B.</given-names></name><etal/></person-group><article-title>Inhibition of radiation-induced glioblastoma invasion by genetic and pharmacological targeting of MDA-9/Syntenin</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2017</year><volume>114</volume><fpage>370</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1073/pnas.1616100114</pub-id><pub-id pub-id-type="pmid">28011764</pub-id></element-citation></ref><ref id="B108-cancers-11-00846"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piperigkou</surname><given-names>Z.</given-names></name><name><surname>Manou</surname><given-names>D.</given-names></name><name><surname>Karamanou</surname><given-names>K.</given-names></name><name><surname>Theocharis</surname><given-names>A.D.</given-names></name></person-group><article-title>Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer</article-title><source>Methods Mol. Biol.</source><year>2018</year><volume>1731</volume><fpage>325</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">29318564</pub-id></element-citation></ref><ref id="B109-cancers-11-00846"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>V&#x000e4;is&#x000e4;nen</surname><given-names>A.</given-names></name><name><surname>Kallioinen</surname><given-names>M.</given-names></name><name><surname>von Dickhoff</surname><given-names>K.</given-names></name><name><surname>Laatikainen</surname><given-names>L.</given-names></name><name><surname>H&#x000f6;yhty&#x000e4;</surname><given-names>M.</given-names></name><name><surname>Turpeenniemi-Hujanen</surname><given-names>T.</given-names></name></person-group><article-title>Matrix metalloproteinase-2 (MMP-2) immunoreactive protein&#x02014;A new prognostic marker in uveal melanoma?</article-title><source>J. Pathol.</source><year>1999</year><volume>188</volume><fpage>56</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-9896(199905)188:1&#x0003c;56::AID-PATH304&#x0003e;3.0.CO;2-B</pub-id><pub-id pub-id-type="pmid">10398141</pub-id></element-citation></ref><ref id="B110-cancers-11-00846"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Shabrawi</surname><given-names>Y.</given-names></name><name><surname>Ardjomand</surname><given-names>N.</given-names></name><name><surname>Radner</surname><given-names>H.</given-names></name><name><surname>Ardjomand</surname><given-names>N.</given-names></name></person-group><article-title>MMP-9 is predominantly expressed in epithelioid and not spindle cell uveal melanoma</article-title><source>J. Pathol.</source><year>2001</year><volume>194</volume><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1002/1096-9896(200106)194:2&#x0003c;201::AID-PATH840&#x0003e;3.0.CO;2-O</pub-id><pub-id pub-id-type="pmid">11400149</pub-id></element-citation></ref><ref id="B111-cancers-11-00846"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>K.</given-names></name><name><surname>Conway</surname><given-names>R.M.</given-names></name><name><surname>Crouch</surname><given-names>R.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name><name><surname>Madigan</surname><given-names>M.C.</given-names></name></person-group><article-title>Expression and distribution of MMPs and TIMPs in human uveal melanoma</article-title><source>Exp. Eye Res.</source><year>2008</year><volume>86</volume><fpage>936</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2008.03.010</pub-id><pub-id pub-id-type="pmid">18423620</pub-id></element-citation></ref><ref id="B112-cancers-11-00846"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>B&#x000e9;liveau</surname><given-names>A.</given-names></name><name><surname>B&#x000e9;rub&#x000e9;</surname><given-names>M.</given-names></name><name><surname>Rousseau</surname><given-names>A.</given-names></name><name><surname>Pelletier</surname><given-names>G.</given-names></name><name><surname>Gu&#x000e9;rin</surname><given-names>S.L.</given-names></name></person-group><article-title>Expression of integrin alpha5beta1 and MMPs associated with epithelioid morphology and malignancy of uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2000</year><volume>41</volume><fpage>2363</fpage><lpage>2372</lpage><pub-id pub-id-type="pmid">10892885</pub-id></element-citation></ref><ref id="B113-cancers-11-00846"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>C.-W.</given-names></name><name><surname>Hsieh</surname><given-names>Y.-H.</given-names></name><name><surname>Yang</surname><given-names>W.-E.</given-names></name><name><surname>Yang</surname><given-names>S.-F.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Hu</surname><given-names>D.-N.</given-names></name></person-group><article-title>Epigallocatechingallate inhibits migration of human uveal melanoma cells via downregulation of matrix metalloproteinase-2 activity and ERK1/2 pathway</article-title><source>BioMed Res. Int.</source><year>2014</year><volume>2014</volume><fpage>141582</fpage><pub-id pub-id-type="doi">10.1155/2014/141582</pub-id><pub-id pub-id-type="pmid">25184134</pub-id></element-citation></ref><ref id="B114-cancers-11-00846"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bi</surname><given-names>M.-C.</given-names></name><name><surname>Hose</surname><given-names>N.</given-names></name><name><surname>Xu</surname><given-names>C.-L.</given-names></name><name><surname>Zhang</surname><given-names>C.</given-names></name><name><surname>Sassoon</surname><given-names>J.</given-names></name><name><surname>Song</surname><given-names>E.</given-names></name></person-group><article-title>Nonlethal Levels of Zeaxanthin Inhibit Cell Migration, Invasion, and Secretion of MMP-2 via NF-&#x003ba;B Pathway in Cultured Human Uveal Melanoma Cells</article-title><source>J. Ophthalmol.</source><year>2016</year><volume>2016</volume><fpage>8734309</fpage><pub-id pub-id-type="doi">10.1155/2016/8734309</pub-id><pub-id pub-id-type="pmid">26942004</pub-id></element-citation></ref><ref id="B115-cancers-11-00846"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maacha</surname><given-names>S.</given-names></name><name><surname>Anezo</surname><given-names>O.</given-names></name><name><surname>Foy</surname><given-names>M.</given-names></name><name><surname>Liot</surname><given-names>G.</given-names></name><name><surname>Mery</surname><given-names>L.</given-names></name><name><surname>Laurent</surname><given-names>C.</given-names></name><name><surname>Sastre-Garau</surname><given-names>X.</given-names></name><name><surname>Piperno-Neumann</surname><given-names>S.</given-names></name><name><surname>Cassoux</surname><given-names>N.</given-names></name><name><surname>Planque</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Protein Tyrosine Phosphatase 4A3 (PTP4A3) Promotes Human Uveal Melanoma Aggressiveness Through Membrane Accumulation of Matrix Metalloproteinase 14 (MMP14)</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2016</year><volume>57</volume><fpage>1982</fpage><lpage>1990</lpage><pub-id pub-id-type="doi">10.1167/iovs.15-18780</pub-id><pub-id pub-id-type="pmid">27096756</pub-id></element-citation></ref><ref id="B116-cancers-11-00846"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gangemi</surname><given-names>R.</given-names></name><name><surname>Amaro</surname><given-names>A.</given-names></name><name><surname>Gino</surname><given-names>A.</given-names></name><name><surname>Barisione</surname><given-names>G.</given-names></name><name><surname>Fabbi</surname><given-names>M.</given-names></name><name><surname>Pfeffer</surname><given-names>U.</given-names></name><name><surname>Brizzolara</surname><given-names>A.</given-names></name><name><surname>Queirolo</surname><given-names>P.</given-names></name><name><surname>Salvi</surname><given-names>S.</given-names></name><name><surname>Boccardo</surname><given-names>S.</given-names></name><etal/></person-group><article-title>ADAM10 correlates with uveal melanoma metastasis and promotes in vitro invasion</article-title><source>Pigment Cell Melanoma Res.</source><year>2014</year><volume>27</volume><fpage>1138</fpage><lpage>1148</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12306</pub-id><pub-id pub-id-type="pmid">25124714</pub-id></element-citation></ref><ref id="B117-cancers-11-00846"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caltabiano</surname><given-names>R.</given-names></name><name><surname>Puzzo</surname><given-names>L.</given-names></name><name><surname>Barresi</surname><given-names>V.</given-names></name><name><surname>Ieni</surname><given-names>A.</given-names></name><name><surname>Loreto</surname><given-names>C.</given-names></name><name><surname>Musumeci</surname><given-names>G.</given-names></name><name><surname>Castrogiovanni</surname><given-names>P.</given-names></name><name><surname>Ragusa</surname><given-names>M.</given-names></name><name><surname>Foti</surname><given-names>P.</given-names></name><name><surname>Russo</surname><given-names>A.</given-names></name><etal/></person-group><article-title>ADAM 10 expression in primary uveal melanoma as prognostic factor for risk of metastasis</article-title><source>Pathol. Res. Pract.</source><year>2016</year><volume>212</volume><fpage>980</fpage><lpage>987</lpage><pub-id pub-id-type="doi">10.1016/j.prp.2016.08.003</pub-id><pub-id pub-id-type="pmid">27546281</pub-id></element-citation></ref><ref id="B118-cancers-11-00846"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winer</surname><given-names>A.</given-names></name><name><surname>Adams</surname><given-names>S.</given-names></name><name><surname>Mignatti</surname><given-names>P.</given-names></name></person-group><article-title>Matrix Metalloproteinase Inhibitors in Cancer Therapy: Turning Past Failures into Future Successes</article-title><source>Mol. Cancer Ther.</source><year>2018</year><volume>17</volume><fpage>1147</fpage><lpage>1155</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-17-0646</pub-id><pub-id pub-id-type="pmid">29735645</pub-id></element-citation></ref><ref id="B119-cancers-11-00846"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Comoglio</surname><given-names>P.M.</given-names></name><name><surname>Trusolino</surname><given-names>L.</given-names></name><name><surname>Boccaccio</surname><given-names>C.</given-names></name></person-group><article-title>Known and novel roles of the MET oncogene in cancer: A coherent approach to targeted therapy</article-title><source>Nat. Rev. Cancer</source><year>2018</year><volume>18</volume><fpage>341</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1038/s41568-018-0002-y</pub-id><pub-id pub-id-type="pmid">29674709</pub-id></element-citation></ref><ref id="B120-cancers-11-00846"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrix</surname><given-names>M.J.</given-names></name><name><surname>Seftor</surname><given-names>E.A.</given-names></name><name><surname>Seftor</surname><given-names>R.E.</given-names></name><name><surname>Kirschmann</surname><given-names>D.A.</given-names></name><name><surname>Gardner</surname><given-names>L.M.</given-names></name><name><surname>Boldt</surname><given-names>H.C.</given-names></name><name><surname>Meyer</surname><given-names>M.</given-names></name><name><surname>Pe&#x02019;er</surname><given-names>J.</given-names></name><name><surname>Folberg</surname><given-names>R.</given-names></name></person-group><article-title>Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF)</article-title><source>Am. J. Pathol.</source><year>1998</year><volume>152</volume><fpage>855</fpage><lpage>863</lpage><pub-id pub-id-type="pmid">9546344</pub-id></element-citation></ref><ref id="B121-cancers-11-00846"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economou</surname><given-names>M.A.</given-names></name><name><surname>All-Ericsson</surname><given-names>C.</given-names></name><name><surname>Bykov</surname><given-names>V.</given-names></name><name><surname>Girnita</surname><given-names>L.</given-names></name><name><surname>Bartolazzi</surname><given-names>A.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Seregard</surname><given-names>S.</given-names></name></person-group><article-title>Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: Intercorrelation and prognostic implications</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2005</year><volume>46</volume><fpage>4372</fpage><lpage>4375</lpage><pub-id pub-id-type="doi">10.1167/iovs.05-0322</pub-id><pub-id pub-id-type="pmid">16303922</pub-id></element-citation></ref><ref id="B122-cancers-11-00846"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mallikarjuna</surname><given-names>K.</given-names></name><name><surname>Pushparaj</surname><given-names>V.</given-names></name><name><surname>Biswas</surname><given-names>J.</given-names></name><name><surname>Krishnakumar</surname><given-names>S.</given-names></name></person-group><article-title>Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study</article-title><source>Curr. Eye Res.</source><year>2007</year><volume>32</volume><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1080/02713680601161220</pub-id><pub-id pub-id-type="pmid">17453948</pub-id></element-citation></ref><ref id="B123-cancers-11-00846"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Topcu-Yilmaz</surname><given-names>P.</given-names></name><name><surname>Kiratli</surname><given-names>H.</given-names></name><name><surname>Saglam</surname><given-names>A.</given-names></name><name><surname>S&#x000f6;ylemezoglu</surname><given-names>F.</given-names></name><name><surname>Hascelik</surname><given-names>G.</given-names></name></person-group><article-title>Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma</article-title><source>Melanoma Res.</source><year>2010</year><volume>20</volume><fpage>126</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1097/CMR.0b013e328335a916</pub-id><pub-id pub-id-type="pmid">20061986</pub-id></element-citation></ref><ref id="B124-cancers-11-00846"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gardner</surname><given-names>F.P.</given-names></name><name><surname>Serie</surname><given-names>D.J.</given-names></name><name><surname>Salomao</surname><given-names>D.R.</given-names></name><name><surname>Wu</surname><given-names>K.J.</given-names></name><name><surname>Markovic</surname><given-names>S.N.</given-names></name><name><surname>Pulido</surname><given-names>J.S.</given-names></name><name><surname>Joseph</surname><given-names>R.W.</given-names></name></person-group><article-title>c-MET expression in primary and liver metastases in uveal melanoma</article-title><source>Melanoma Res.</source><year>2014</year><volume>24</volume><fpage>617</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1097/CMR.0000000000000118</pub-id><pub-id pub-id-type="pmid">25211165</pub-id></element-citation></ref><ref id="B125-cancers-11-00846"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barisione</surname><given-names>G.</given-names></name><name><surname>Fabbi</surname><given-names>M.</given-names></name><name><surname>Gino</surname><given-names>A.</given-names></name><name><surname>Queirolo</surname><given-names>P.</given-names></name><name><surname>Orgiano</surname><given-names>L.</given-names></name><name><surname>Spano</surname><given-names>L.</given-names></name><name><surname>Picasso</surname><given-names>V.</given-names></name><name><surname>Pfeffer</surname><given-names>U.</given-names></name><name><surname>Mosci</surname><given-names>C.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name><etal/></person-group><article-title>Potential Role of Soluble c-Met as a New Candidate Biomarker of Metastatic Uveal Melanoma</article-title><source>JAMA Ophthalmol.</source><year>2015</year><volume>133</volume><fpage>1013</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1001/jamaophthalmol.2015.1766</pub-id><pub-id pub-id-type="pmid">26068448</pub-id></element-citation></ref><ref id="B126-cancers-11-00846"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Surriga</surname><given-names>O.</given-names></name><name><surname>Rajasekhar</surname><given-names>V.K.</given-names></name><name><surname>Ambrosini</surname><given-names>G.</given-names></name><name><surname>Dogan</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>R.</given-names></name><name><surname>Schwartz</surname><given-names>G.K.</given-names></name></person-group><article-title>Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model</article-title><source>Mol. Cancer Ther.</source><year>2013</year><volume>12</volume><fpage>2817</fpage><lpage>2826</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-13-0499</pub-id><pub-id pub-id-type="pmid">24140933</pub-id></element-citation></ref><ref id="B127-cancers-11-00846"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Selvan</surname><given-names>S.</given-names></name><name><surname>McCue</surname><given-names>P.A.</given-names></name><name><surname>DeAngelis</surname><given-names>T.</given-names></name><name><surname>Baserga</surname><given-names>R.</given-names></name><name><surname>Fujii</surname><given-names>A.</given-names></name><name><surname>Rui</surname><given-names>H.</given-names></name><name><surname>Mastrangelo</surname><given-names>M.J.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name></person-group><article-title>Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth</article-title><source>Pigment Cell Melanoma Res.</source><year>2014</year><volume>27</volume><fpage>297</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1111/pcmr.12206</pub-id><pub-id pub-id-type="pmid">24354797</pub-id></element-citation></ref><ref id="B128-cancers-11-00846"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Economou</surname><given-names>M.A.</given-names></name><name><surname>Andersson</surname><given-names>S.</given-names></name><name><surname>Vasilcanu</surname><given-names>D.</given-names></name><name><surname>All-Ericsson</surname><given-names>C.</given-names></name><name><surname>Menu</surname><given-names>E.</given-names></name><name><surname>Girnita</surname><given-names>A.</given-names></name><name><surname>Girnita</surname><given-names>L.</given-names></name><name><surname>Axelson</surname><given-names>M.</given-names></name><name><surname>Seregard</surname><given-names>S.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name></person-group><article-title>Oral picropodophyllin (PPP) is well tolerated in vivo and inhibits IGF-1R expression and growth of uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2008</year><volume>49</volume><fpage>2337</fpage><lpage>2342</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-0819</pub-id><pub-id pub-id-type="pmid">18515579</pub-id></element-citation></ref><ref id="B129-cancers-11-00846"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girnita</surname><given-names>A.</given-names></name><name><surname>All-Ericsson</surname><given-names>C.</given-names></name><name><surname>Economou</surname><given-names>M.A.</given-names></name><name><surname>Astr&#x000f6;m</surname><given-names>K.</given-names></name><name><surname>Axelson</surname><given-names>M.</given-names></name><name><surname>Seregard</surname><given-names>S.</given-names></name><name><surname>Larsson</surname><given-names>O.</given-names></name><name><surname>Girnita</surname><given-names>L.</given-names></name></person-group><article-title>The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells</article-title><source>Acta Ophthalmol. (Copenh.)</source><year>2008</year><volume>86 Thesis 4</volume><fpage>26</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1755-3768.2008.01183.x</pub-id></element-citation></ref><ref id="B130-cancers-11-00846"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Filali</surname><given-names>M.</given-names></name><name><surname>van der Velden</surname><given-names>P.A.</given-names></name><name><surname>Luyten</surname><given-names>G.P.M.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Anti-angiogenic therapy in uveal melanoma</article-title><source>Dev. Ophthalmol.</source><year>2012</year><volume>49</volume><fpage>117</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">22042017</pub-id></element-citation></ref><ref id="B131-cancers-11-00846"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Notting</surname><given-names>I.C.</given-names></name><name><surname>Missotten</surname><given-names>G.S.O.A.</given-names></name><name><surname>Sijmons</surname><given-names>B.</given-names></name><name><surname>Boonman</surname><given-names>Z.F.H.M.</given-names></name><name><surname>Keunen</surname><given-names>J.E.E.</given-names></name><name><surname>van der Pluijm</surname><given-names>G.</given-names></name></person-group><article-title>Angiogenic profile of uveal melanoma</article-title><source>Curr. Eye Res.</source><year>2006</year><volume>31</volume><fpage>775</fpage><lpage>785</lpage><pub-id pub-id-type="doi">10.1080/02713680600865052</pub-id><pub-id pub-id-type="pmid">16966150</pub-id></element-citation></ref><ref id="B132-cancers-11-00846"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Missotten</surname><given-names>G.S.O.</given-names></name><name><surname>Notting</surname><given-names>I.C.</given-names></name><name><surname>Schlingemann</surname><given-names>R.O.</given-names></name><name><surname>Zijlmans</surname><given-names>H.J.</given-names></name><name><surname>Lau</surname><given-names>C.</given-names></name><name><surname>Eilers</surname><given-names>P.H.C.</given-names></name><name><surname>Keunen</surname><given-names>J.E.E.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Vascular endothelial growth factor a in eyes with uveal melanoma</article-title><source>Arch. Ophthalmol.</source><year>2006</year><volume>124</volume><fpage>1428</fpage><lpage>1434</lpage><pub-id pub-id-type="doi">10.1001/archopht.124.10.1428</pub-id><pub-id pub-id-type="pmid">17030710</pub-id></element-citation></ref><ref id="B133-cancers-11-00846"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Filali</surname><given-names>M.</given-names></name><name><surname>Missotten</surname><given-names>G.S.O.A.</given-names></name><name><surname>Maat</surname><given-names>W.</given-names></name><name><surname>Ly</surname><given-names>L.V.</given-names></name><name><surname>Luyten</surname><given-names>G.P.M.</given-names></name><name><surname>van der Velden</surname><given-names>P.A.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Regulation of VEGF-A in uveal melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2010</year><volume>51</volume><fpage>2329</fpage><lpage>2337</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-4739</pub-id><pub-id pub-id-type="pmid">20042655</pub-id></element-citation></ref><ref id="B134-cancers-11-00846"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barak</surname><given-names>V.</given-names></name><name><surname>Pe&#x02019;er</surname><given-names>J.</given-names></name><name><surname>Kalickman</surname><given-names>I.</given-names></name><name><surname>Frenkel</surname><given-names>S.</given-names></name></person-group><article-title>VEGF as a biomarker for metastatic uveal melanoma in humans</article-title><source>Curr. Eye Res.</source><year>2011</year><volume>36</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.3109/02713683.2010.534573</pub-id><pub-id pub-id-type="pmid">21284506</pub-id></element-citation></ref><ref id="B135-cancers-11-00846"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name><name><surname>Grossniklaus</surname><given-names>H.E.</given-names></name></person-group><article-title>Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2010</year><volume>51</volume><fpage>2835</fpage><lpage>2842</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-4755</pub-id><pub-id pub-id-type="pmid">20089875</pub-id></element-citation></ref><ref id="B136-cancers-11-00846"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francis</surname><given-names>J.H.</given-names></name><name><surname>Kim</surname><given-names>J.</given-names></name><name><surname>Lin</surname><given-names>A.</given-names></name><name><surname>Folberg</surname><given-names>R.</given-names></name><name><surname>Iyer</surname><given-names>S.</given-names></name><name><surname>Abramson</surname><given-names>D.H.</given-names></name></person-group><article-title>Growth of Uveal Melanoma following Intravitreal Bevacizumab</article-title><source>Ocul. Oncol. Pathol.</source><year>2017</year><volume>3</volume><fpage>117</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1159/000450859</pub-id><pub-id pub-id-type="pmid">28868282</pub-id></element-citation></ref><ref id="B137-cancers-11-00846"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El Filali</surname><given-names>M.</given-names></name><name><surname>Ly</surname><given-names>L.V.</given-names></name><name><surname>Luyten</surname><given-names>G.P.M.</given-names></name><name><surname>Versluis</surname><given-names>M.</given-names></name><name><surname>Grossniklaus</surname><given-names>H.E.</given-names></name><name><surname>van der Velden</surname><given-names>P.A.</given-names></name><name><surname>Jager</surname><given-names>M.J.</given-names></name></person-group><article-title>Bevacizumab and intraocular tumors: An intriguing paradox</article-title><source>Mol. Vis.</source><year>2012</year><volume>18</volume><fpage>2454</fpage><lpage>2467</lpage><pub-id pub-id-type="pmid">23077404</pub-id></element-citation></ref><ref id="B138-cancers-11-00846"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarhini</surname><given-names>A.A.</given-names></name><name><surname>Frankel</surname><given-names>P.</given-names></name><name><surname>Margolin</surname><given-names>K.A.</given-names></name><name><surname>Christensen</surname><given-names>S.</given-names></name><name><surname>Ruel</surname><given-names>C.</given-names></name><name><surname>Shipe-Spotloe</surname><given-names>J.</given-names></name><name><surname>Gandara</surname><given-names>D.R.</given-names></name><name><surname>Chen</surname><given-names>A.</given-names></name><name><surname>Kirkwood</surname><given-names>J.M.</given-names></name></person-group><article-title>Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal origin</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2011</year><volume>17</volume><fpage>6574</fpage><lpage>6581</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-11-1463</pub-id></element-citation></ref><ref id="B139-cancers-11-00846"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piperno-Neumann</surname><given-names>S.</given-names></name><name><surname>Diallo</surname><given-names>A.</given-names></name><name><surname>Etienne-Grimaldi</surname><given-names>M.-C.</given-names></name><name><surname>Bidard</surname><given-names>F.-C.</given-names></name><name><surname>Rodrigues</surname><given-names>M.</given-names></name><name><surname>Plancher</surname><given-names>C.</given-names></name><name><surname>Mariani</surname><given-names>P.</given-names></name><name><surname>Cassoux</surname><given-names>N.</given-names></name><name><surname>Decaudin</surname><given-names>D.</given-names></name><name><surname>Asselain</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Phase II Trial of Bevacizumab in Combination with Temozolomide as First-Line Treatment in Patients with Metastatic Uveal Melanoma</article-title><source>Oncologist</source><year>2016</year><volume>21</volume><fpage>281</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2015-0501</pub-id><pub-id pub-id-type="pmid">26911405</pub-id></element-citation></ref><ref id="B140-cancers-11-00846"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>K.</given-names></name><name><surname>Babapoor-Farrokhran</surname><given-names>S.</given-names></name><name><surname>Rodrigues</surname><given-names>M.</given-names></name><name><surname>Deshpande</surname><given-names>M.</given-names></name><name><surname>Puchner</surname><given-names>B.</given-names></name><name><surname>Kashiwabuchi</surname><given-names>F.</given-names></name><name><surname>Hassan</surname><given-names>S.J.</given-names></name><name><surname>Asnaghi</surname><given-names>L.</given-names></name><name><surname>Handa</surname><given-names>J.T.</given-names></name><name><surname>Merbs</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>7816</fpage><lpage>7828</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.6868</pub-id><pub-id pub-id-type="pmid">26761211</pub-id></element-citation></ref><ref id="B141-cancers-11-00846"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lattanzio</surname><given-names>L.</given-names></name><name><surname>Tonissi</surname><given-names>F.</given-names></name><name><surname>Torta</surname><given-names>I.</given-names></name><name><surname>Gianello</surname><given-names>L.</given-names></name><name><surname>Russi</surname><given-names>E.</given-names></name><name><surname>Milano</surname><given-names>G.</given-names></name><name><surname>Merlano</surname><given-names>M.</given-names></name><name><surname>Lo Nigro</surname><given-names>C.</given-names></name></person-group><article-title>Role of IL-8 induced angiogenesis in uveal melanoma</article-title><source>Investig. New Drugs</source><year>2013</year><volume>31</volume><fpage>1107</fpage><lpage>1114</lpage><pub-id pub-id-type="doi">10.1007/s10637-013-0005-1</pub-id><pub-id pub-id-type="pmid">23912257</pub-id></element-citation></ref><ref id="B142-cancers-11-00846"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Kageyama</surname><given-names>K.</given-names></name><name><surname>Ozaki</surname><given-names>S.</given-names></name><name><surname>McCue</surname><given-names>P.A.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Aplin</surname><given-names>A.E.</given-names></name></person-group><article-title>Paracrine Effect of NRG1 and HGF Drives Resistance to MEK Inhibitors in Metastatic Uveal Melanoma</article-title><source>Cancer Res.</source><year>2015</year><volume>75</volume><fpage>2737</fpage><lpage>2748</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-15-0370</pub-id><pub-id pub-id-type="pmid">25952648</pub-id></element-citation></ref><ref id="B143-cancers-11-00846"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Chua</surname><given-names>V.</given-names></name><name><surname>Liao</surname><given-names>C.</given-names></name><name><surname>Purwin</surname><given-names>T.J.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Kageyama</surname><given-names>K.</given-names></name><name><surname>Davies</surname><given-names>M.A.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name><name><surname>Aplin</surname><given-names>A.E.</given-names></name></person-group><article-title>Co-targeting HGF/cMET Signaling with MEK Inhibitors in Metastatic Uveal Melanoma</article-title><source>Mol. Cancer Ther.</source><year>2017</year><volume>16</volume><fpage>516</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-16-0552</pub-id><pub-id pub-id-type="pmid">28138035</pub-id></element-citation></ref><ref id="B144-cancers-11-00846"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mahipal</surname><given-names>A.</given-names></name><name><surname>Tijani</surname><given-names>L.</given-names></name><name><surname>Chan</surname><given-names>K.</given-names></name><name><surname>Laudadio</surname><given-names>M.</given-names></name><name><surname>Mastrangelo</surname><given-names>M.J.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name></person-group><article-title>A pilot study of sunitinib malate in patients with metastatic uveal melanoma</article-title><source>Melanoma Res.</source><year>2012</year><volume>22</volume><fpage>440</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1097/CMR.0b013e328358b373</pub-id><pub-id pub-id-type="pmid">23114504</pub-id></element-citation></ref><ref id="B145-cancers-11-00846"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valsecchi</surname><given-names>M.E.</given-names></name><name><surname>Orloff</surname><given-names>M.</given-names></name><name><surname>Sato</surname><given-names>R.</given-names></name><name><surname>Chervoneva</surname><given-names>I.</given-names></name><name><surname>Shields</surname><given-names>C.L.</given-names></name><name><surname>Shields</surname><given-names>J.A.</given-names></name><name><surname>Mastrangelo</surname><given-names>M.J.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name></person-group><article-title>Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma: Comparison with Institutional Controls</article-title><source>Ophthalmology</source><year>2018</year><volume>125</volume><fpage>210</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.ophtha.2017.08.017</pub-id><pub-id pub-id-type="pmid">28935400</pub-id></element-citation></ref><ref id="B146-cancers-11-00846"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mouriaux</surname><given-names>F.</given-names></name><name><surname>Servois</surname><given-names>V.</given-names></name><name><surname>Parienti</surname><given-names>J.J.</given-names></name><name><surname>Lesimple</surname><given-names>T.</given-names></name><name><surname>Thyss</surname><given-names>A.</given-names></name><name><surname>Dutriaux</surname><given-names>C.</given-names></name><name><surname>Neidhart-Berard</surname><given-names>E.M.</given-names></name><name><surname>Penel</surname><given-names>N.</given-names></name><name><surname>Delcambre</surname><given-names>C.</given-names></name><name><surname>Peyro Saint Paul</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Sorafenib in metastatic uveal melanoma: Efficacy, toxicity and health-related quality of life in a multicentre phase II study</article-title><source>Br. J. Cancer</source><year>2016</year><volume>115</volume><fpage>20</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/bjc.2016.119</pub-id><pub-id pub-id-type="pmid">27253171</pub-id></element-citation></ref><ref id="B147-cancers-11-00846"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>W.-T.</given-names></name><name><surname>Wu</surname><given-names>J.-F.</given-names></name><name><surname>Yu</surname><given-names>G.-Y.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Li</surname><given-names>L.-H.</given-names></name><name><surname>Chen</surname><given-names>P.</given-names></name><name><surname>Jiang</surname><given-names>Y.-N.</given-names></name><name><surname>Cheng</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>H.W.</given-names></name><etal/></person-group><article-title>Suppression of tumor angiogenesis by targeting the protein neddylation pathway</article-title><source>Cell Death Dis.</source><year>2014</year><volume>5</volume><fpage>e1059</fpage><pub-id pub-id-type="doi">10.1038/cddis.2014.21</pub-id><pub-id pub-id-type="pmid">24525735</pub-id></element-citation></ref><ref id="B148-cancers-11-00846"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jin</surname><given-names>B.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Pan</surname><given-names>J.</given-names></name></person-group><article-title>Neddylation Blockade Diminishes Hepatic Metastasis by Dampening Cancer Stem-Like Cells and Angiogenesis in Uveal Melanoma</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>3741</fpage><lpage>3754</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-17-1703</pub-id></element-citation></ref><ref id="B149-cancers-11-00846"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scala</surname><given-names>S.</given-names></name><name><surname>Ieran&#x000f2;</surname><given-names>C.</given-names></name><name><surname>Ottaiano</surname><given-names>A.</given-names></name><name><surname>Franco</surname><given-names>R.</given-names></name><name><surname>La Mura</surname><given-names>A.</given-names></name><name><surname>Liguori</surname><given-names>G.</given-names></name><name><surname>Mascolo</surname><given-names>M.</given-names></name><name><surname>Staibano</surname><given-names>S.</given-names></name><name><surname>Ascierto</surname><given-names>P.A.</given-names></name><name><surname>Botti</surname><given-names>G.</given-names></name><etal/></person-group><article-title>CXC chemokine receptor 4 is expressed in uveal malignant melanoma and correlates with the epithelioid-mixed cell type</article-title><source>Cancer Immunol. Immunother.</source><year>2007</year><volume>56</volume><fpage>1589</fpage><lpage>1595</lpage><pub-id pub-id-type="doi">10.1007/s00262-007-0303-6</pub-id><pub-id pub-id-type="pmid">17410362</pub-id></element-citation></ref><ref id="B150-cancers-11-00846"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Victor</surname><given-names>N.</given-names></name><name><surname>Ivy</surname><given-names>A.</given-names></name><name><surname>Jiang</surname><given-names>B.-H.</given-names></name><name><surname>Agani</surname><given-names>F.H.</given-names></name></person-group><article-title>Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells</article-title><source>Clin. Exp. Metastasis</source><year>2006</year><volume>23</volume><fpage>87</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1007/s10585-006-9024-z</pub-id><pub-id pub-id-type="pmid">16826425</pub-id></element-citation></ref><ref id="B151-cancers-11-00846"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L.</given-names></name><name><surname>You</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Osuka</surname><given-names>S.</given-names></name><name><surname>Devi</surname><given-names>N.S.</given-names></name><name><surname>Kaluz</surname><given-names>S.</given-names></name><name><surname>Ferguson</surname><given-names>J.H.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Arylsulfonamide 64B Inhibits Hypoxia/HIF-Induced Expression of c-Met and CXCR4 and Reduces Primary Tumor Growth and Metastasis of Uveal Melanoma</article-title><source>Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>2206</fpage><lpage>2218</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-1368</pub-id><pub-id pub-id-type="pmid">30563937</pub-id></element-citation></ref><ref id="B152-cancers-11-00846"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Yang</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>P.W.</given-names></name><name><surname>Alizadeh</surname><given-names>H.</given-names></name><name><surname>Niederkorn</surname><given-names>J.Y.</given-names></name></person-group><article-title>Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2009</year><volume>50</volume><fpage>5522</fpage><lpage>5528</lpage><pub-id pub-id-type="doi">10.1167/iovs.09-3804</pub-id><pub-id pub-id-type="pmid">19553629</pub-id></element-citation></ref><ref id="B153-cancers-11-00846"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Z.</given-names></name><name><surname>Zhan</surname><given-names>W.</given-names></name><name><surname>Zhu</surname><given-names>A.</given-names></name><name><surname>Yoon</surname><given-names>Y.</given-names></name><name><surname>Lin</surname><given-names>S.</given-names></name><name><surname>Sasaki</surname><given-names>M.</given-names></name><name><surname>Klapproth</surname><given-names>J.-M.A.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Grossniklaus</surname><given-names>H.E.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Development of a unique small molecule modulator of CXCR4</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><elocation-id>e34038</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0034038</pub-id><pub-id pub-id-type="pmid">22485156</pub-id></element-citation></ref><ref id="B154-cancers-11-00846"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Niederkorn</surname><given-names>J.Y.</given-names></name><name><surname>Sadegh</surname><given-names>L.</given-names></name><name><surname>Mellon</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>P.W.</given-names></name></person-group><article-title>Epigenetic regulation of CXCR4 expression by the ocular microenvironment</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2013</year><volume>54</volume><fpage>234</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1167/iovs.12-10643</pub-id><pub-id pub-id-type="pmid">23188729</pub-id></element-citation></ref><ref id="B155-cancers-11-00846"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bosch</surname><given-names>T.</given-names></name><name><surname>Koopmans</surname><given-names>A.E.</given-names></name><name><surname>Vaarwater</surname><given-names>J.</given-names></name><name><surname>van den Berg</surname><given-names>M.</given-names></name><name><surname>de Klein</surname><given-names>A.</given-names></name><name><surname>Verdijk</surname><given-names>R.M.</given-names></name></person-group><article-title>Chemokine receptor CCR7 expression predicts poor outcome in uveal melanoma and relates to liver metastasis whereas expression of CXCR4 is not of clinical relevance</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2013</year><volume>54</volume><fpage>7354</fpage><lpage>7361</lpage><pub-id pub-id-type="doi">10.1167/iovs.13-12407</pub-id><pub-id pub-id-type="pmid">24052640</pub-id></element-citation></ref><ref id="B156-cancers-11-00846"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Alizadeh</surname><given-names>H.</given-names></name><name><surname>Niederkorn</surname><given-names>J.Y.</given-names></name></person-group><article-title>Differential expression of chemokine receptors on uveal melanoma cells and their metastases</article-title><source>Investig. Ophthalmol. Vis. Sci.</source><year>2008</year><volume>49</volume><fpage>636</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1167/iovs.07-1035</pub-id><pub-id pub-id-type="pmid">18235009</pub-id></element-citation></ref><ref id="B157-cancers-11-00846"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onken</surname><given-names>M.D.</given-names></name><name><surname>Worley</surname><given-names>L.A.</given-names></name><name><surname>Ehlers</surname><given-names>J.P.</given-names></name><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death</article-title><source>Cancer Res.</source><year>2004</year><volume>64</volume><fpage>7205</fpage><lpage>7209</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-1750</pub-id><pub-id pub-id-type="pmid">15492234</pub-id></element-citation></ref><ref id="B158-cancers-11-00846"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harbour</surname><given-names>J.W.</given-names></name></person-group><article-title>A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile</article-title><source>Methods Mol. Biol.</source><year>2014</year><volume>1102</volume><fpage>427</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">24258991</pub-id></element-citation></ref><ref id="B159-cancers-11-00846"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kageyama</surname><given-names>K.</given-names></name><name><surname>Ohara</surname><given-names>M.</given-names></name><name><surname>Saito</surname><given-names>K.</given-names></name><name><surname>Ozaki</surname><given-names>S.</given-names></name><name><surname>Terai</surname><given-names>M.</given-names></name><name><surname>Mastrangelo</surname><given-names>M.J.</given-names></name><name><surname>Fortina</surname><given-names>P.</given-names></name><name><surname>Aplin</surname><given-names>A.E.</given-names></name><name><surname>Sato</surname><given-names>T.</given-names></name></person-group><article-title>Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis</article-title><source>J. Transl. Med.</source><year>2017</year><volume>15</volume><fpage>145</fpage><pub-id pub-id-type="doi">10.1186/s12967-017-1247-z</pub-id><pub-id pub-id-type="pmid">28645290</pub-id></element-citation></ref><ref id="B160-cancers-11-00846"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Babchia</surname><given-names>N.</given-names></name><name><surname>Landreville</surname><given-names>S.</given-names></name><name><surname>Cl&#x000e9;ment</surname><given-names>B.</given-names></name><name><surname>Coulouarn</surname><given-names>C.</given-names></name><name><surname>Mouriaux</surname><given-names>F.</given-names></name></person-group><article-title>The bidirectional crosstalk between metastatic uveal melanoma cells and hepatic stellate cells engenders an inflammatory microenvironment</article-title><source>Exp. Eye Res.</source><year>2019</year><volume>181</volume><fpage>213</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1016/j.exer.2019.02.012</pub-id><pub-id pub-id-type="pmid">30771295</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="cancers-11-00846-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Main signaling pathways downstream G&#x003b1;Q or G&#x003b1;11 and their inhibitors. Inhibitors of specific signaling molecules are depicted in red line boxes. GPCR: G protein-coupled receptor; CYSLT2R: Cysteinyl leukotriene receptor 2; PKC&#x003b4;/&#x003b5;: Protein kinase C delta/epsilon; RASGRP3: RAS guanyl releasing protein 3; PLC&#x003b2;: Phospholipase C beta; DAG: Diacylglycerol; PIP2: Phosphatidylinositol biphosphate; IP3: Inositol 1,4,5-trisphosphate; ARF6: ADP ribosylation factor 6; TRIO: Trio rho guanine nucleotide exchange factor; RHO: Ras homologue family member; ROCK: Rho-associated, coiled-coil-containing protein kinase; Rac: Rac family small GTPase 1; FAK: Focal adhesion kinase; MOB1: MOB kinase activator 1; LATS: Large tumor suppressor kinase; Yap: Yes associated protein 1; PI3K: Phosphatidylinositol-4,5-bisphosphate 3-kinase. This figure was adapted from Yang et al. [<xref rid="B1-cancers-11-00846" ref-type="bibr">1</xref>].</p></caption><graphic xlink:href="cancers-11-00846-g001"/></fig><table-wrap id="cancers-11-00846-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">cancers-11-00846-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of targeted therapy clinical trials in Uveal Melanoma (UM).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Clinical Trial</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Intervention (N&#x000b0; of Patients)</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Phase</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Status [Reference]</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Date</th></tr></thead><tbody><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">MEK inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01143402</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Selumetinib in comparison to chemotherapy (120)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, has results [<xref rid="B39-cancers-11-00846" ref-type="bibr">39</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010&#x02013;2017</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02768766</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intermittent Selumetinib (28)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#x02013;2019</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01974752</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SUMIT <sup>1</sup> selumetinib or placebo in combination with dacarbazine (152)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, has results [<xref rid="B40-cancers-11-00846" ref-type="bibr">40</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013&#x02013;2017</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EudraCT 2014-004437-22</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">selumetinib and paclitaxel (72 planned)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ongoing, no longer recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2019</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PKC inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02601378</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LX196 as a single agent and in combination with HDM201 <sup>2</sup> (122 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2019</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">PI3K/AKT/MTOR inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01801358</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AEB071 and Binimetinib, MEK162 (38)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1b/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated for scientific reasons before the initiation of the Phase II</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013&#x02013;2016</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02273219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AEB071 and BYL719 (30 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014&#x02013;2018</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01979523</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trametinib with or without GSK2141795 (44 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed [<xref rid="B41-cancers-11-00846" ref-type="bibr">41</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013&#x02013;2018</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01252251</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RAD001, Everolimus and Pasireotide, SOM230 LAR (14)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, has results [<xref rid="B42-cancers-11-00846" ref-type="bibr">42</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010&#x02013;2017</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">HDAC <sup>3</sup> inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01587352</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vorinostat, NSC 701852 (23)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#x02013;2018</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT03022565</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vorinostat (10 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Early phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2019&#x02013;2026</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02068586</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adjuvant Sunitinib or Valproic acid (150 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2014&#x02013;2021</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02697630</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pembrolizumab and Entinostat (29 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2018&#x02013;2023</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">BET <sup>4</sup> inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02683395</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLX51107 (50)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 1b/2a</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Terminated (Business Decision)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2016&#x02013;2018</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Tyrosine kinase receptor MET <sup>5</sup></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02223819</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Crizotinib (34 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Active, not recruiting</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2015&#x02013;2019</td></tr><tr><td colspan="5" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Multi-tyrosine kinase inhibitors</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT01835145</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cabozantinib compared with Temozolomide or Dacarbazine (47)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed </td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2013&#x02013;2016</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT02517736</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sorafenib, Nexavar<sup>&#x000ae;</sup> (32 estimated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2012&#x02013;2015</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NCT00329641</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BAY 43-9006, Sorafenib With Carboplatin and Paclitaxel (25)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Completed, has results [<xref rid="B43-cancers-11-00846" ref-type="bibr">43</xref>]</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2011&#x02013;2012</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EudraCT 2008-008794-55</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sunitinib versus Dacarbazine (84)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ended</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2010&#x02013;2014</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1</sup> Selumetinib in Metastatic Uveal Melanoma; <sup>2</sup> human double minute 2 homolog (HDM2) inhibitor; <sup>3</sup> Histone Deacetylase; <sup>4</sup> Bromodomain and Extra-Terminal motif; <sup>5</sup> MET Proto-Oncogene, Receptor Tyrosine Kinase.</p></fn></table-wrap-foot></table-wrap></floats-group></article>